Year	First Author	No	Sex	Age	Site	Complications	Treatment	Incision	LOS (days)

1991 [13]	Hale	22	M	85	Sigmoid	Incarceration	Hartmann’s + intra-abdominal internal ring closure	Midline laparotomy	NA

2003 [12]	Tan	23	M	62	Sigmoid	Incarceration	High anterior resection + left orchidectomy + intra-abdominal closure of hernial defect	Left iliac fossa transverse	NA

2003 [7]	Kouraklis	24	M	79	Sigmoid	Perforation	Hartmann’s + loop colostomy + interval reversal and open hernioplasty	Left groin	10

2003 [16]	Cervinka	25	M	69	Sigmoid	Incarceration	Sigmoidectomy + anastomosis + defunctioning transverse colostomy + herniorrhaphy (Bassini)	Left groin	NA

2008 [17]	Slater	26	M	66	Sigmoid	Incarceration	Hartmann’s + left orchidectomy + internal ring closure	Left groin + midline laparotomy	NA

2008 [17]	Slater	27	M	73	Sigmoid	Perforation	Hartmann’s + left orchidectomy + internal ring closure	L groin + Left modified Rutherford-Morrison	NA

2009 [18]	Ruiz-Tovar	28	M	67	Sigmoid	Perforation without contamination	Sigmoidectomy and anastomosis + hernioplasty (Lichtenstein)	Left groin + midline laparotomy	7

2010 [19]	Ko	29	M	84	Sigmoid	Perforation	Hartmann’s + herniorrhaphy	Laparotomy	Deceased

2010 [20]	Mai	30	M	83	Sigmoid	Strangulation	Hartmann’s + herniorrhaphy	Lower midline + left groin	NA

2011 [5]	Pernazza	31	M	70	Caecum	Incarceration	Laparoscopic right hemicolectomy + herniorrhaphy	Laparoscopy + bilateral groin incisions	5

2012 [6]	Carr	32	M	65	Sigmoid	Incarceration	Laparoscopic high anterior resection + open biosynthetic hernioplasty	Laparoscopy + left groin	4

2013 [21]	Meniconi	33	F	78	Caecum	Incarceration	Open right hemicolectomy + herniorrhaphy	Midline laparotomy + right groin	NA

2013 [22]	Tan	34	M	63	Sigmoid	Perforation	Hartmann’s + herniorrhaphy	Midline laparotomy + left groin	10

2016 [23]	Kulasegaran	35	M	66	Sigmoid	Perforation + necrotising infection	Hartmann’s + debridement + staged skin graft	Left groin + midline laparotomy	NA

2016 [24]	Diao	36	M	48	Transverse colon	Perforation	Transverse colectomy + herniorrhaphy + orchidectomy + partial scrotectomy	Left groin	NA

2017 [25]	Sharma	37	M	84	Caecum	None	Open right hemicolectomy + herniorrhaphy	Right transverse	NA

2018	Current report	38	M	83	Ascending colon	Incarceration	Laparoscopic right hemicolectomy + laparoscopic defect closure	Laparoscopy	10


	Normotensive pregnancy (n = 3183)	Gestational hypertension (n = 145) Beta (95% CI)	P value	Pre-eclampsia (n = 63) Beta (95% CI)	P value

Retinal arteriolar caliber (SDS)

 Full model	Ref	–0.20 (–0.34, –0.05)	0.007	–0.40 (–0.62, –0.19)	0.0002

Retinal venular caliber (SDS)

 Full model	Ref	0.22 (0.07–0.36)	0.003	0.08 (–0.13, 0.30)	0.45


Statistical value 	DR: VC	DR: RMSSD	DR: max-min	VR	Rest: VC	Rest: RMSSD	DR: max/min	PI

Ancova F	10.854	8.492	9.016	0.380	6.512	0.493	6.467	2.70

p-value	<0.01	<0.04	<0.005	n.s.	<0.02	n.s.	<0.02	n.s.


Targeta	Nucleotide sequence (5′ to 3′)	Amplicon size (bp)	Reference

cfbb	F: CACACATGCTGTTGGAGTTCAGTTGA	138	This study

R: ACGAAGTCGACAGCATCACACGAAA

erm(A)/(TR)	F: CCGGCAAGGAGAAGGTTATAATGA	190	Otaguiri et al. [5]

R: GCATTCACCCGTTGACTCATTTCC

erm(B)	F: GCTCTTGCACACTCAAGTCTCGAT	117	Otaguiri et al. [5]

R: ACATCTGTGGTATGGCGGGTAAGT

mef(A/E)	F: GCGATGGTCTTGTCTATGGCTTCA	225	Otaguiri et al. [5]

R: AGCTGTTCCAATGCTACGGAT

RNaseP	F: AGATTTGGACCTGCGAGCG	64	WHO [27]

R: GAGCGGCTGTCTCCACAAGT

IGS1	F: GTCATTTCAGCTGGCGCCATCGATAC	260	Tavares et al. [32]

R: TTGCCGCATAACGCATCTTAGCCA


Outcome	RCN (monetized)	ASBL (monetized)	SER (monetized)	ASBL + SER (monetized)

Cycling mode share by 2051 (%)	5	20	5	40

LV mode share by 2051 (%)	75	65	55	40

Proportion of people considering cycling always/mostly safe by 2040	0.4	0.7	0.3	0.9

LVKT (billion km)	–3.5	–7	–10	–18.5

Cyclist injuries

Fatalities	200 (620)	360 (1,100)	85 (250)	250 (850)

Serious injuries	4,000 (1,300)	7,000 (2,300)	1,600 (500)	5,000 (1,600)

Car crashes

Car occupant fatalities	–70 (–220)	–120 (–370)	–170 (–527)	–340 (–1,000)

Air pollution

Mortality	–10 (–7.5)	–20 (–15)	–40 (–30)	–80 (–60)

Hospitalizations	–5 (–0.02)	–15 (–0.04)	–20 (–0.06)	–40 (–0.12)

COPD incidence	–10 (–0.75)	–30 (–2.25)	–55 (–4)	–90 (–6.75)

Restricted activity days	–12,500 (–1)	–37,200 (–4)	–57,700 (–6)	–112,200 (–11)

Air pollution total	(–9)	(–21)	(–40)	(–78)

All-cause mortality	–650 (–2,000)	–1,850 (–5,700)	–650 (–2,000)	–4,000 (–12,400)

Greenhouse gas emissions (megatons)	–3 (–120)	–8 (–360)	–13 (–520)	–26 (–1040)

Fuel cost ($NZ million)	(–600)	(–1,800)	(–600)	(–3,900)

Infrastructure cost ($NZ million)	(45)	(250)	(380)	(630)

Net benefit ($NZ million)	–770	–2,550	–1,780	–13,090

Benefit–cost ratio	18	18	6	24

Abbreviations: LV, light vehicle; LVKT, light vehicle kilometers travelled. Numbers with a negative sign represent savings. Monetized figures are given in parentheses and are in millions of New Zealand dollars. Benefit–cost ratios are calculated from the net public health benefits and infrastructure costs shown.


Protein Symbol	Protein Name	Organism	Function	Swiss Prot ID

OPN (SSP1)	Osteopontin, secreted phosphoprotein 1	Homo sapiens	Matrix mineralization, immunity	P10451

DMP1	Dentin matrix protein 1	Homo sapiens	Osteoblast differentiation, nucleation of hydroxyapatite	Q13316

MEPE	Matrix extracellular phosphoglycoprotein	Homo sapiens	Phosphate excretion, mineralization	Q9NQ76

BSP	Bone sialoprotein	Homo sapiens	Matrix mineralization, hydroxyapatite binding, cell attachment	P21815

DSPP	Dentin sialophosphoprotein	Homo sapiens	Dentinogenesis	Q9NZW4

AMELX	Amylogenin	Homo sapiens	Enamel formation; extracellular scaffold, crystal growth	Q99217

Stm	Starmaker	Danio rerio (zebrafish)	Otolith formation	A2VD23

OMM-64	Otolith matrix macromolecule-64	Oncorhynchus mykiss (rainbow trout)	Otolith formation	B1Q2L9


Question	Response rate (percentage; n = 86)

14. How did you usually use the video clips in PHARMACY 301?	79

15. How did watching the Pharmville clips help you in PHARMACY 301?	64

16. Which families are the most realistic and why?	35

17. Which are the most unrealistic and why?	28

18. Do you have any suggestions for improving Pharmville?	48

19. Do you have any suggestions for where else the Pharmville families could be included in the BPharm programme?	19

20. How do feel that Pharmville and the related clips helped your learning?	35

21. Space for any other comments about Pharmville that you would like to make.	17


UHI Assessment TOOL	Geographical Cover	Scale of the Assessment	Type of Assessment	User Input Parameters	Tool Output

Decision Support System (DSS) UHI project	Bologna/Modena, Venice/Padua, Wien, Stuttgart, Lodz/Warsaw, Ljubljana, Budapest and Prague.	Supra-metropolitan	Phase 1: Mapping Urban Heat. Phase 2: Understanding regulations and policies related to UHI (greenery: street or roof, material reflectance...)	1/Location, 2/Scale (building or urban) 3/Typology of the intervention (building, facade, roofs, surface lots, urban structure and urban green) 4/Economic assessment 5/Skills.	1/climate change assessment (Change in annual mean temperature per decade, changes in annual near-surface temperature for 30 year periods and heat wave frequency), 2/a set of normative applicable to the selected area and skills, 3/a set of potential mitigation strategies.

CE Urban Heat Island Atlas UHI project	Central Europe region	Regional	Phase 1: Mapping Urban heat related parameters.	1/Location	1/Air temperature 2/Digital elevation models 3/Land surface temperature 4/Land cover regional scale (corine) 5/Urban land use.

STAR tools GRaBS project	North West region of England	Neighbourhood	Phase 4: Testing conceptual design	1/Location 2/Land cover proposal (% of buildings, major roads, other impervious surfaces, green and blue surfaces and bare soil or gravel surfaces) 3/Temperature scenario for 2050 (Baseline temperature, 2050’s 10% probability level, 50% probability level or 90% probability level).	1/Maximum surface temperature

London unified model (Londum)	City of London	City	Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city.	1/ Volume (Reflection, Shadowing, conduction of heat into the buildings, flux of heat into the atmosphere). Provided by the tool for the city of London.	1/Urban heat island intensity (air temperature at 1,5m height).

ADMS model	City of London	Neighbourhood	Phase 1: Simluation map of the Urban Heat Island of the existing city. Phase 4: Simulation map of the Urban Heat Island of the projected city.	1/Location 2/Surface cover (Albedo, evapotranspiration, thermal admittance).	2/Air temperature variations -due to land cover- at 2m height.

London site-specific air temperature prediction model (LSSAT)	City of London	Neighbourhood	Phase 1: Air temperature mapping at a particular time. Phase 4: Air temperature prediction based on intervention proposed.	1/Location	1/Hourly prediction of air temperature based on site specific transects (Global solar radiation, cloud cover, wind velocity and relative humidity).

EPA Mitigation Impact Screening Tool (MIST)	U.S.A. 230 cities	City	Phase 4: Testing the mitigation effect of the selected mitiation strategy.	1/Location 2/The latitude 3/the cooling degree day (CDD) 4/the heating degree day (HDD) 5/the population 6/the mean annual temperature 7/the typical peak (one hour) ozone 8/Mitigation strategy (albedo or vegetation modification).	Calculation of the effect of the mitigation strategy 1/Reduction of the mean city temperature 2/Cooling degree days 3/the heating degree day 4/the typical 1hr and 8hr max ozone 5/The energy consumption.


Pharmacological agents	Neonatal rat spinal cord preparation	Decerebrate cat preparation	Acute spinal cat	Early chronic spinal cat	Late chronic spinal cat	Late chronic spinal rat

Edrophonium (EDRO)	↑↑			↔

AChE inhibitor

Neostigmine (NEO)	↑↑

AChE inhibitor

EDRO + ACh				↔

AChE inhibitor + acetylocholine

EDRO + tubocurarine	↔

AChE inhibitor + nicotinic antagonist

Clonidine			↑↑

NA agonist

EDRO + clonidine				↑↑

AChE inhibitor+ NA agonist

Clonidine (low dose)			↔

NA agonist

Atropine		↔	↔	↑↑

muscarinic antagonist

Atropine + clonidine (low dose)			↑↑

muscarinic antagonist + NA agonist

Clonidine (low dose) + atropine			↑↑

NA agonist + muscarinic antagonist

Carbachol				↓↓		↓↓

cholinergic agonist

Carbachol + atropine				↑↑		↑↑

cholinergic agonist + muscarinic antagonist

Atropine + carbachol				↓↓

muscarinic antagonist + cholinergic agonist

EDRO + atropine	↑↓↓

AChE inhibitor + muscarinic antagonist

EDRO + telenzepine	↔

AChE inhibitor + M1 antagonist

EDRO + telenzepine (high dose)	↓↓

AChE inhibitor + M1 antagonist

EDRO + methoctramine (METHOC)	↑↓

AChE inhibitor + M2 antagonist

EDRO + METHOC (high dose)	↓↓

AChE inhibitor + M2 antagonist

EDRO + 4-diphenylacetoxy-N-methylpiperidine metiodide (4-DAMP)	↓↓				↑↑

AChE inhibitor + M3 antagonist

MT-3	↔

M4 antagonist

Mecamylamine		↔

nicotinic antagonist

Mecamylamine + atropine		↔

nicotinic antagonist + muscarinic antagonist

Dihydro-β-erythrpidine					↑↑

nicotinic antagonist


Patient	Age	Site	Stage	Primary date	Primary therapy*	Recurrence	Expiry

1	50	Retromolar trigone	IV	2009/05/30	S+CCRT

2	55	Oral tongue	IV	2010/10/24	S+CCRT

3	59	Buccal mucosa	IV	2011/05/04	S+CCRT

4	56	Buccal mucosa	IV	2010/05/31	S+CCRT	2010/08/09	2010/10/31

5	49	Buccal mucosa	IV	2010/07/27	S+CCRT	2010/11/24	2011/06/07

6	48	Buccal mucosa	III	2009/10/06	S+C/T	2009/12/29	2010/02/11


	Acid fast bacilli	Total

	negative for AFB	positive for AFB

Giant cells

 Not present	50	25	75

 Present	6	19	25

Total	56	44	100


Parameter	P-value

Region	0.027

Age	0.103

Gender	0.168

Histology	0.906

Stage	0.901

Smoking status	0.668

Diabetes mellitus	0.142


	Pneumonia (n=5709)

	Without rickets	With rickets

	n=5600	n=109

Deaths n (%)	345 (6.16)	9 (8.26)

Odds-ratio	1.37 (p-value = 0.32)

	Severe malnutrition (n=727)

	Without rickets	With rickets

	n=680	n=47

Deaths n (%)	88 (12.94)	2 (4.26)

Odds-ratio	0.30 (p-value = 0.11)

	Malnutrition (Severe, moderate, mild) (n=1150)

	Without rickets	With rickets

	n=1079	n=71

Deaths n (%)	118 (10.94)	3 (4.23)

Odds-ratio	0.36 (p-value = 0.11)

	Dehydration (n=2233)

	Without rickets	With rickets

	n=2180	n=53

Deaths n (%)	230 (10.55)	4 (7.55)

Odds-ratio	0.69 (p-value = 0.65)

	Diarrhea, n=2805

	Without Rickets	With Rickets

	n=2772	n=33

Deaths n (%)	172 (6.2)	2 (6.06)

Odds-ratio	0.97 (p-value=1.00)


State	NE level	Ih	Apical function

Asleep	Low	High	Isolated from soma

Awake	Moderate	Moderate	Selective amplification

Attentive	High	Low	Inc. Selectivity & Amplif.

High arousal	Maximum	Minimum	Selective drive e.g., Stereotypical impulses

Anesthetized Ketamine propofol Isoflurane	Low	Minimum	Non-selective slow waves


	Mean	SD	Maximum	Minimum

Maximum level of low back pain in the past year	8.81	1.13	10	7

Number of days without pain in the past year	37.04	51.82	174	0

Number of days with low pain in the past year	149.37	86.12	303	0

Number of days with moderate pain in the past year	119.29	51.94	210	22

Number of days with high pain in the past year	57.04	68.72	262	0


Pathogen	Number of patients	Gender (male/female) 	Median age (min–max)	Mortality (%) (survivors/death)

S. pneumoniae 	14	5/81	5.5 (0–40)	46% (7/6)1

N. meningitidis 	22	10/92	5.5 (1–60)	27% (16/6)

H. influenzae 	9	7/2	2 (1–4)	0% (9/0)


Author	Derivation sample	Validation sample	Predictors	Outcomes	Performance in the validation sample	Presentation of a simplified score

Pillai et al.	208 patients from India with severe TBI	26 patients from the same centre	1-oculocephalic reflex2-motor GCS3-midline shift	Death or vegetative state	Sensitivity (75%)Specificity (67%)PPV 50%	No

Signorini et al	372 patients from Scotland with moderate and severe TBI	520 patients from the same centre	1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan)	Survival at 1 year	A.U.R.O.C (0.835)Error rate (15.2%)Brier score (0.1160)Hosmer-Lemeshow(p < 0.001)	Nomogram

Signorini et al	110 patients from Scotland with moderate and severe TBI	140 patients from the same centre	1-GCS2-ISS3-pupils reactivity and 4-haematoma (CT scan)5-ICP measures	Survival at 1 year	Not reported	No

Hukkelhoven et al.	134 patients from Netherlands with moderate and severe TBI	180 patients from the same centre	1-age2-motor GCS3-pupils reactivity4-pupillary size5-hypotension6-ISS	Raised ICP	A.U.R.O.C. (0.50)Hosmer-Lemeshow(p = 0.18)	No

Hukkelhoven et al.	275 patients from Netherlands with moderate and severe TBI	250 patients from the same centre	1-age2-cause of injury3-pupils reactivity4-pupillary size5-hypotension6-ISS	Surgical removable lesions	A.U.R.O.C. (0.67)Hosmer-Lemeshow(p = 0.01)	No

Hukkelhoven et al.	2269 patients from 2 trials in high income countries with moderate and severe TBI	796 patients from Europe	1-age2-motorGCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage	Death or disability at 6 months	A.U.R.O.C. (0.83)Hosmer-Lemeshow(p = 0.05)	Score chart

Hukkelhoven et al.	2269 patients from 2 trials in high income countries with moderate and severe TBI	796 patients from Europe and 746 from the United States	1-age2-motor GCS3-pupils reactivity4-hypoxia5-hypotension6-CT classification7-subarachnoid haemorrhage	Death at 6 months	A.U.R.O.C. (0.87/0.89)Hosmer-Lemeshow(p = 0.42/<0.001)	Score chart


 	Mild TBI	Moderate TBI	Severe TBI	p-value

Number of patients	229	85	54	-

Age at time of injury (years)

Mean ± standard deviation	23.7 ± 16.6	29.0 ± 20.9	22.5 ± 16.4	0.038

Range (minimum - maximum)	1.0 - 66.0	1.0 - 76.0	1.0 - 60.0

median	20.0	28.0	19.0

Age at time of reexamination (years)

Mean ± standard deviation	44.2 ± 16.9	43.4 ± 20.08	26.5 ± 16.5	0.018

Range (minimum - maximum)	12.0 - 87.0	11.0 - 87.0	12.0 - 76.0

median	41.0	42.0	34.5

Time to reexamination (years)

Mean ± standard deviation	20.3 ± 6.5	14.2 ± 4.1	14.0 ± 3.9	<0.001

Number of patients <18 years	101	33	26	0.531

(%)	(44.1%)	(38.8%)	(48.1%)

Gender distribution (♂: ♀)	129: 100	57: 28	40: 14	0.026

Injury Severity (ISS)	-	14.8 ± 7.5	21.4 ± 7.1	<0.001

New Injury Severity (NISS)	-	24.3 ± 12.3	36.3 ± 14.8	<0.001

Marital status at follow-up

- Single	40.7%	42.2%	64.8%	0.010

 - Married or cohabitant	51.0%	50.6%	24.1%

 - Divorced	8.3%	7.2%	11.1%

Housing situation before TBI

 - in rented accommodation	51.2%	46.8%	38.5%	0.249

Housing situation at follow-up

 - in rented accommodation	50.2%	42.0%	38.5%	0.205

 - confinement in bed	0.0%	0.0%	5.6%	<0.001


Method	MDR	AntEpiSeeker	BOOST	MegaSNPHunter	KNN-MDR

Power	N/A	0.65	0.67	0.80	0.74

Corrected power	N/A	0.15	0.28	0.12	0.63


Ricketts analysis	Pretreatment (16 years, 4 months)	Posttreatment (19 years, 8 months)

Norm	Value	Deviation	Norm	Value	Deviation

Cranial relations

 Facial axis (°)	90 ± 3.5	88.4	vertical growth type	90 ± 3.5	89.0	dolichofacial face type

 Mandibular plane (°)	23.6 ± 4	34.0	29.6 ± 4	29.9

 Mandibular arc (°)	26 ± 4	30.1	27.7 ± 4	26.4

 Lower facial height (°)	45 ± 4	54.1	45 ± 4	58.1

 Maxillary depth (°)	90 ± 3	87.4	maxilla ortho- to retrognathic	90 ± 3	89.7	maxilla orthognathic

 SN-Palatal plane (°)	7.3 ± 3	−3.3	anterior rotation of maxilla	7.3 ± 3	−1.2	less anterior rotation of maxilla

 Facial (angle) depth (°)	89.4 ± 3	84.6	mandible prognathic	90.6 ± 3	85.7	mandible prognathic

 Facial taper	68 ± 3	61.4	posterior rotation of mandible	68 ± 3	64.4	less posterior rotation of mandible

 Convexity of point A (mm)	−0.4 ± 2	2.6	slight skeletal class III	−1.6 ± 2	3.8	skeletal class III

Denture Relations

 Upper incisor to A-Pog (mm)	3.5 ± 2	10.7	distinctly protruded	3.5 ± 2	9.6	slightly less protruded

 Upper incisor to FH (°)	111 ± 4	105.5	slightly retroinclined	111 ± 4	107.4	normally inclined

 Upper molar to PtV(mm)	19.3 ± 1	15.2	upper dental arch retruded	22.7 ± 1	18.3	upper dental arch retruded

 Lower incisor to A-Pog (mm)	1 ± 2	6.5	distinctly protruded	1 ± 2	7.1	distinctly protruded

 Lower incisor inclination (°)	22 ± 4	24.5	normally inclined	22 ± 4	23.4	normally inclined

 Interincisal angle (°)	130 ± 6	132.4	normal	130 ± 6	131.8	normal

 Molar relation (mm)	−3.0 ± 2	−2.6	Angle class I	−3.0 ± 2	−1.1	Angle class I

 Incisor Overjet (mm)	2.5 ± 1	4.6	increased	2.5 ± 1	2.5	normal

 Incisor Overbite (mm)	2.5 ± 1	3.2	increased	2.5 ± 1	2.2	normal

Esthetic Relations

 Lower lip – E-Plane(mm)	−2 ± 2	−3.9	lower lip slightly retruded	< -2 ± 2	−4.3	lower lip slightly retruded


Author	Year, Country	Investigation period	No. of colic cases	Distribution of cases	Cases euthanized or dead %	Short-term survival rates (%)

 	Medical %	Surgical %	Without any treatment	Medical cases	Cases undergoing surgery

 	During surgery	After recovery	Overall	Medically treated cases	Surgically treated cases

[3]	1989, USA	1974-1984	320	41	59	16	6	31	25	59	94	44

[7]	2005, Germany	1990-1997	1431	80	20	*	7	35	16	84	93	49

[5]	2003, The Netherlands	1999-2000	649	64	36	8	15	26	21	69	85	54

[6]	2005, Canada	1992-2002	604	54	46	21	6	26	14	66	94	60

[8]	2009, Israel	2003-2006	208	30	70	6	8**	34	71	92	66

[9]	2009, South Africa	1998-2007	929	60	40	3	7	21	13	79	93	66

UHLA***	2013, Denmark	2000-2009	1588	69	31	10	13	44	14	68	87	42


Place, author's and years of Examination	Prevalence of schistosomiasis

Schistosoma haematobium %	Schistosoma mansoni %

This study

Before mass treatment 2002	13.6	36.3

After mass treatment 2008	18.6	31.0

Mali (Clements et al.) (26)

Before mass treatment (1989)	25.7	7.4

After mass treatment (2006)	38.3	6.7

Mali (Landoure A et al.) (27)

Before mass treatment (2004)	88.0	17.0

After mass treatment (2010)	61.0	12.0

Tanzania (Poggensee G et al.) (28)

Before mass treatment 1996	36.7	22.9

After mass treatment 2002	33.6	00.7


Cigarettes: ‘surgeon general’s warning’	Smokeless tobacco: ‘warning’

Smoking causes lung cancer, heart disease, emphysema, and may complicate pregnancy	This product may cause mouth cancer

Quitting smoking now greatly reduces serious risks to your health	This product may cause gum disease and tooth loss

Smoking by pregnant women may result in fetal injury, premature birth, and low birth weight	Proposed: this product contains nicotine and is addictive

Cigarette smoke contains carbon monoxide	Compromise: this product is not a safe alternative to cigarettes


Primer Name	Sequence	Gene

CSnmrAF	AGTAGGGTAGGCAGCATCCA	Check for PC-06 (NmrA)

CSnmrAR	GCGCACTATTTCTGAGCAGC	Check for PC-06

pen1	ATGTCCAGATCCCTAACCCAC	Screen for penP deletion

pen2	CATAATTGGGGTCACCTGATG	Screen for penP deletion

CSpenCF	CGTCGACAGAATCTCCAGCT	Check for penC

CSpenCR	TCATCCATCACACCGCGATT	Check for penC

CSjanCF	GGGGAAGGTAGCCATGCTTT	Check for janC

CSjanCR	TGCGGATATTACGAGGCGAC	Check for janC

jan1	CCAATGTTAGAGTCCCAACG	Screen for jan P deletion

jan2	GTCGTATACTCCCCGACATG	Screen for jan P deletion

CSP450F	ACGGTCACGGTCAAGTCTTC	Check for PJ-13 (P450)

CSP450R	CGTTACAGGGCCGGGTATTT	Check for PJ-13 (P450)

CSjanQF	TACAGGCCAGCTCTTCAACC	Check for janQ

CSjanQR	TCGGACATCTTTCGCACCAA	Check for janQ

CS janD intF	GGACTTACAAGGCTTTCGCA	Screen for janD deletion

CS janD intR	ACGCTTAAAGCCCAGAAACA	Screen for janD deletion

CSFADF	CTTCCTCGTGCCCTTGACAT	Check for janO (FAD)

CSFADR	GACCATGCTGTACCGAACGT	Check for janO (FAD)


Translocation	Translocation partner	ATRA response

t(11;17) (q23;q21) [5]	PLZF (promyelocytic leukaemia zinc finger protein)	Resistant

t(5;17) (q35;q21) [6]	NPM (nucleophosmin)	Sensitive

t(11;17) (q13;q21) [7]	NUMA (nuclear mitotic apparatus)	Sensitive

der(17) [8]	STAT5b (signal transducer and activator of transcription)	Resistant

t(3;15) (q26;q13) (present case)		Sensitive


1. Was an 'a priori' design provided?The research question and inclusion criteria should be established before the conduct of the review.	□ Yes□ No□ Can't answer□ Not applicable

2. Was there duplicate study selection and data extraction?There should be at least two independent data extractors and a consensus procedure for disagreements should be in place.	□ Yes□ No□ Can't answer□ Not applicable

3. Was a comprehensive literature search performed?At least two electronic sources should be searched. The report must include years and databases used (e.g. Central, EMBASE, and MEDLINE). Key words and/or MESH terms must be stated and where feasible the search strategy should be provided. All searches should be supplemented by consulting current contents, reviews, textbooks, specialized registers, or experts in the particular field of study, and by reviewing the references in the studies found.	□ Yes□ No□ Can't answer□ Not applicable

4. Was the status of publication (i.e. grey literature) used as an inclusion criterion?The authors should state that they searched for reports regardless of their publication type. The authors should state whether or not they excluded any reports (from the systematic review), based on their publication status, language etc.	□ Yes□ No□ Can't answer□ Not applicable

5. Was a list of studies (included and excluded) provided?A list of included and excluded studies should be provided.	□ Yes□ No□ Can't answer□ Not applicable

6. Were the characteristics of the included studies provided?In an aggregated form such as a table, data from the original studies should be provided on the participants, interventions and outcomes. The ranges of characteristics in all the studies analyzed e.g. age, race, sex, relevant socioeconomic data, disease status, duration, severity, or other diseases should be reported.	□ Yes□ No□ Can't answer□ Not applicable

7. Was the scientific quality of the included studies assessed and documented?'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the author(s) chose to include only randomized, double-blind, placebo controlled studies, or allocation concealment as inclusion criteria); for other types of studies alternative items will be relevant.	□ Yes□ No□ Can't answer□ Not applicable

8. Was the scientific quality of the included studies used appropriately in formulating conclusions?The results of the methodological rigor and scientific quality should be considered in the analysis and the conclusions of the review, and explicitly stated in formulating recommendations.	□ Yes□ No□ Can't answer□ Not applicable

9. Were the methods used to combine the findings of studies appropriate?For the pooled results, a test should be done to ensure the studies were combinable, to assess their homogeneity (i.e. Chi-squared test for homogeneity, I2). If heterogeneity exists a random effects model should be used and/or the clinical appropriateness of combining should be taken into consideration (i.e. is it sensible to combine?).	□ Yes□ No□ Can't answer□ Not applicable

10. Was the likelihood of publication bias assessed?An assessment of publication bias should include a combination of graphical aids (e.g., funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test).	□ Yes□ No□ Can't answer□ Not applicable

11. Was the conflict of interest stated?Potential sources of support should be clearly acknowledged in both the systematic review and the included studies.	□ Yes□ No□ Can't answer□ Not applicable


Nutrient	Amount (DM)

Crude protein	76.9%

Crude fat	1.9%

Ca	12.31%

P	1.03%

Na	4.09%

K	0.3%

Mg	2.08%

S	0.24%

Mn	615 ppm

Zn	924 ppm

Cu	308 ppm

Co	26 ppm

I	87 ppm

Se	6–8 ppm

Vitamin A	90,200 IU/kg

Vitamin D	9020 IU/kg

Vitamin E	226 IU/kg

Rumensin® 0.68 g/kg	616 g/t

Tylan ® 0.14 g/kg	123 g/t


#	m/z	z	m	Sequence proposal	Alignment	Protein homologue

1	1185.6	3	3553.8	SNVLYGPDTPTLSQSLGNS	Query: NVLYGPDTPTLSQS	CEACAM8

					NVLYGPD PT+S S	P31997

					Sbjct: NVLYGPDAPTISPS	H. sapiens

2	693.3	3	2076.9	BXXTVESVPPNAAEGKDALLR	Query: TVESVPPNAAEGKDALL	CEACAM8

	1039	2			T+E VP NAAEGK+ LL	P31997

					Sbjct: TIEAVPSNAAEGKEVLL	H. sapiens

3	553.2	2	1104.4	BVTTPGPAYSGR	Query: TPGPAYSGR	CEACAM8

					TPGPAYS R	P31997

					Sbjct: TPGPAYSNR	H. sapiens

4	656.8	4	2623.2	B [VL]LPGDTASLTWFK [W/GE/AD/SV]TVLPXXK	Query: WFKGETV	CEACAM8

	875.4	3			W+KGETV	P31997

					Sbjct: WYKGETV	H. sapiens

5	539.2	2	1076.4	BLLLYVLDTK	Query: BLLLYVLDT	Q9NOP7

					+++ YV+ T	CEA protein

					Sbjct: RIIGYVIAT	P. hamadryas

6	425.2	2	848.4	BFETALLR	No match

7	386.2	2	770.4	BTVPDSPR	No match


	Nutritional factors	Chick -starter diet	Chick-Grower diet

1.	ME* Kcal/ kg	2915	2915

2.	Crude protein %	17.50	15.00

3.	Fat %	3-4	3-4

4.	Fibre %	3-4	3-4

5.	Lysine %	0.70	0.75

6.	Methionine %	0.40	0.35

7.	Calcium %	1.00	1.00

8.	Total Phosphorus %	0.70	0.60

9.	Vitamin A (I.U.)	4550	4450

10.	Vitamin D (I.U.)	1600	1600

11.	Vitamin E (I.U.)	15.0	15.0

12.	Vitamin K (mg)	1.00	1.00

13.	Choline (mg)	45.0	45.0

14.	Linoleic acid %	1.00	1.00


Assumptions	Justification

66.45% of standard care monitoring occurs in primary care with practice nurses	Based on previous TAR (manufacturers submission for TA256)70

60% of the cohort have atrial fibrillation, 40% have an artificial heart valve	In line with the observed proportions of patients with these conditions in self-monitoring trials68

Average age of the cohort is 65 years, and 55% are male	In line with the observed mean age of included patients with these conditions in self-monitoring trials68

50% of self-monitoring people self-test, 50% self-manage	Self- assumption

The increase in the number of tests performed per year with self-monitoring is 23	In line with the observed frequency of self-testing in self-monitoring trials68

Relative treatment effects are estimated and applied separately for self-testing and self-management	Derived from the observed event rates in cohorts of people being managed under current standard models of care. Relative risks of these events resulting from improved/reduced INR control, conferred by self-monitoring, were derived from the meta-analysis of RCTs of self-monitoring versus standard practice. (see section on clinical effectiveness results)

15% of participants do not commence self-monitoring following training	Based on the RCT literature43 and the expert advisory committee consultation

10% of participants discontinue self-monitoring within a year of commencing	Based on consideration of the views of the expert advisory committee (∼5%) and a rate of 14% reported in the largest UK-based trial.43

Self-monitoring device costs are annuitized over 5 years to account for the potential for loss and accidental damage	It was assumed that the NHS would pay for devices and loan them out to patients. As such they were annuitized over their expected useful life, to provide an equivalent annual/quarterly cost of use

75% of devices are reused by another patient when a patient discontinues self-monitoring	In line with a previous UK-based economic evaluation71


Clinical Features	Colombia	Mexico	Latinos USA (NLAAS)	USA(NCS-R)

	n¥	%(95%CI)*	n¥	%(95%CI)*	n¥	%(95%CI)*	n¥	%(95%CI)*

Recurrent hazard-laden smoking	9	3 (1, 5)	7	3 (<1, 5)	15	6 (3, 9)	59	3 (2, 4)

Social problems	13	5 (2, 7)	8	3 (<1, 5)	5	2 (<1, 3)	27	1 (1, 2)

Continued smoking despite experiencing these problems‡	9	4 (1, 6)	6	2 (<1, 4)	4	2 (<1, 3)	22	1 (1, 2)

Work problems	8	2 (<1, 4)	6	2 (<1, 4)	5	1 (<1, 3)	24	1 (<1, 2)

Legal problems	6	2 (<1, 4)	3	1 (<1, 2)	Not available**	5	Not estimated


	ECW	ECS	ECT	NW

ECW	1			0.33

ECS	1	1		0.33

ECT	1	1	1	0.33


groups	Rhizoma Coptidis	Radix Scutellariae	Cortex Phellodendri	Fructus Gardeniae

F1	3	2	2	3

F2	6	2	2	3

F3	3	4	4	6

F4	3	4	2	12

F5	3	2	8	6

F6	3	8	4	3

F7	12	4	8	3

F8	6	1	2	6

F9	6	4	1	3


Reagent	AS	DRG	LB	KOH	NP/PEG

Metabolites	Terpenes and steroids	Alkaloids	Triterpenes and steroids	Coumarins and anthraquinones	Flavonoids andphenolic acids	Saponins

L. origanoides leaves

HEFL	++	−	+	+	+	−

DIFL	+	−	+	+	+	−

EAFL	+	−	+	−	++	+

AQFL	+	−	+	−	+	+

L. origanoides stems

HEFS	++	−	+	+	−	−

DIFS	+	−	+	−	+	−

EAFS	+	−	+	−	++	+

AQFS	+	−	+	−	+	+


Variable	Patients with vascular events (n = 7)	Patients without vascular events(n = 83)

Age (years), median (IQR) 	47 (31–62)	50 (40–62)

Males, n (%)	4 (57.1%)	43 (51.8%)

Personal history VTE, n (%)	1 (14.3%)	6 (7.2%)

Family history VTE, n (%)	1 (14.3%)	7 (8.4%)

Unprovoked SVT, n (%)	2 (28.6%)	31 (37.4%)

Liver cirrhosis, n (%)	3 (42.9%)	11 (13.3%)

Solid cancer, n (%)	0 (0%)	6 (7.2%)

Myeloproliferative neoplasm, n (%)	1 (14.3%)	6 (7.2%)

Recent abdominal surgery, n (%)	0 (0%)	10 (12.1%)

Hormonal therapy, n (%)*	1 (33.3%)	10 (25.0%)

Inflammatory bowel disease, n (%)	0 (0%)	5 (6.0%)

JAK2 V617F mutation, n (%)**	1 (20.0%)	2 (5.4%)

Factor V Leiden or prothrombin G20210A mutation, n (%)**	1 (20.0%)	8 (16.0%)

Previous VKA treatment duration (months), median (IQR)	9.9 (3.2–12.9)	12.7 (7.2–24.0)

Time within therapeutic range (%), median (IQR)	68 (67–80)	62 (56–75)

Antiplatelet therapy during follow-up, n (%)	2 (28.6%)	12 (14.5%)


Tests	Patient’s data	Units	Reference ranges

Cortisol dynamic	1 (confirmed twice)	nmol/L

ACTH	46.2	pg/mL	<46.0

Na+	134	mmol/L	136 to 145

K+	4.1	mmol/L	3.3 to 4.8

Cl-	112	mmol/L	98 to 108

Urea	52	mg/dL	12 to 40

Creatinine	2.4	mg/dL	0.7 to 1.2

Ca2+	9.3	mg/dL	8.9 to 10.2

Random glucose	119	mg/dL

Magnesium	2.49	mg/dL	1.7 to 2.55

ALT	5	g/dL	0 to 41

AST	24	U/L	0 to 40

Alkaline phosphatase	53	U/L	40 to 129

Albumin	3.4	g/dL	3.4 to 4.8

Total bilirubin	0.3	mg/dL	0 to 1.0

Tissue transglutaminase	2.7	U/mL	<15

T4	10.6	pmol/L	11.5 to 22.7

T3	2.7	pmol/L	3.5 to 6.5

TSH	10.61	μIU/mL	0.55 to 4.78

ATG	82.5	IU/mL	<100

ATPO	670.7 (+ve)	IU/mL	<50

Anti-adrenal antibodies	Negative	 	<1:10

Blood culture	Negative

Urine culture	Negative

Stool culture	Negative


Food item	Adjusted OR* (95 % CI)	P value

Cold appetizer—pork liver	3.23 (1.26–8.30)	0.01

Lamb chops, carrots, radish wrapped in lotus leaves	3.98 (1.74–9.11)	0.001


Diet	Echolocation Call Type	Bat Species

Fruits	Broadband clicks of short duration	Egyptian fruit bat

Moths, beetles, flies and other insects	Narrowband with dominant fundamental harmonic	Eastern red bat

Flying insects and small fruits	Multiharmonic narrowband, faintly audible to humans	Black-bearded tomb bat

Aquatic insects like midges, crane flies and black flies	Short, broadband, with dominant fundamental harmonic	Daubenton’s bat

Large insects, spiders and small vertebrates	Short, multiharmonic broadband	Greater false vampire bat

Moths	Long, multiharmonic broadband	Madagascar sucker-footed bat

Butterfly, moths and beetles	Constant frequency (CF) & Frequency Modulated (FM)	Greater horseshoe bat

Beetles, moths, flies, wasps, and flying ants 	Downswept FM narrowband	Big brown bat

Beetles, moths, flies, and small insects	FM broadband	Townsend’s big-eared bat


Variables	Univariate	Multivariate

P value	P value	OR (95% CI)

Control group

 Age, y	0.041	0.125

 Female sex	0.463

 AF duration, months	0.008	0.016	1.013 (1.002–1.023)

 NYHA class	0.094	0.130

 Diabetes	0.127	0.394

 Hypertension	0.250

 LAD, mm	0.114	0.246

Long duration group

 Age, y	0.594

 Female sex	0.424

 AF duration, months	0.064	0.049	1.007 (1.001–1.013)

 NYHA class	0.397

 Diabetes	0.205	0.084

 Hypertension	0.044	0.008	1.062 (1.016–1.110)

 LAD, mm	0.310


Sample	Chemical Composition (in wt %)

Ni	Ti	Al

NiTi46	54.0	46.0	-

NiTiAl1	53.5	45.5	1.0

NiTiAl3	52.4	44.6	3.0

NiTiAl5	51.3	43.7	5.0

NiTiAl7	50.2	42.8	7.0


Surgical procedure classification (three-character ICD 10 code)	Number of hospital discharges	Number of adverse events (%)	Degree of disability (no. of patients)

			Sick leave ≤ 3 months	1-15%	16-30%	> 30%	Death

Primary prosthetic replacement of hip joint (NFB**)	50,733	304 (0.6)	18	259	22	4	1

Primary prosthetic replacement of knee joint (NGB**)	23,600	187 (0.8)	12	163	9	2	1

Decompression of spinal cord and nerve roots (ABC**)	17,507	168 (1.0)	12	120	12	22	2

Fracture surgery of femur (NFJ**)	68,123	105 (0.2)	9	80	14	1	1

Fracture surgery of ankle and foot femur (NHJ**)	22,490	103 (0.5)	8	92	2	2	0

Fracture surgery of knee and lower leg (NGJ**)	12,594	92 (0.7)	5	84	3	0	0


Simulation Parameters	Value

map dimension	2 km × 1.5 km

Simulation time	1000 sec

Vehicle speed	0–15 m/s

Velocity threshold	7 m/s

MAC/PHY	IEEE 802.11p

Vehicle density	100–500

Route generator	SUMO


	HFNO group	Venturi mask group	P value

(n = 52)	(n = 48)

Primary endpoint

 Number (%) of patients requiring mechanical ventilation	8 (15 %)	4 (8 %)	0.36

Noninvasive mechanical ventilation	6a	3a

Invasive mechanical ventilation	4	2

Secondary endpoints, median [25th–75th percentile]

 Discomfort VAS scoreb at 120 min	3 [1–5]	3 [0–5]	0.88

 Dyspnea VAS scoreb at 120 min	3 [2 – 6]	3 [1–6]	0.87

 Thirst VAS scoreb at 120 min	6 [3–8]	6 [5 – 9]	0.40

 Respiratory rate at 120 min, breaths/min	25 [22–29]	25 [21–31]

 Heart rate at 120 min, beats/min	98 [90–110]	99 [83–112]	0.43


Gene-set ID	Gene-set Description	Gene N#

hi015	Predicted haploinsufficiency (most inclusive)	8862

hi035	Predicted haploinsufficiency	4136

hi055	Predicted haploinsufficiency (most stringent)	2214

ExpsNov_BrainFeAd_sp	Specific expression in human adult or fetal brain (Novartis Tissue Atlas)	1285

Synapse_GrantFull	Post-synaptic density components	1407

FMR1_Targets_Darnell	FMR1 targets (Darnell et al)	840

FMR1_Targets_Ascano	FMR1 targets (Ascano et al)	927

thrEXPR_log2rpkm	Expressed in brain (BrainSpan)	13802

thr4.86_log2rpkm	Expressed in brain, very high (BrainSpan)	4595

thr3.32_log2rpkm	Expressed in brain, high/medium (BrainSpan)	4604

thr0.84_log2rpkm	Expressed in brain, medium/low (BrainSpan)	4603

thr.MIN_log2rpkm	Not expressed in brain (BrainSpan)	4600

PhHs_NervSys_ADX	Human nervous system phenotype (HPO), autosomal dominant or X-linked	620

PhHs_NervSys_All	Human nervous system phenotype (HPO)	784

PhHs_MindFun_ADX	Higher mental function phenotype (HPO), autosomal dominant or X-linked	395

PhHs_MindFun_All	Higher mental function phenotype (HPO)	687

MmHs_Neuro_All	Mouse neuro phenotype (MGI/MPO)	3479

MmHs_Extend_All	Mouse developmental phenotype (MGI/MPO)	4314

NeuroF_large	Neurobiological function, inclusive	2601

NeuroF_small	Neurobiological function, stringent	1088

Total	Total gene count	18203


Performance objectives	Determinants

Information/knowledge	Self-efficacy/skills

To own LLINs	Explain the benefits of LLINs ownership	Demonstrate how a net should be used

To fight bedbugs	Explain the importance of fighting bedbugs as hindrances of LLINs use	Demonstrate how the technique should be done using hot water and local laundry powder soap (OMO)

To use LLINs every night	Explain the importance of using LLINs every night	Use of LLINs in spite of warm weather or weather changes

To allow IRS at household level	Describe IRS benefits	Allow IRS in master roomAllow IRS in storage rooms

To cover households water collection instruments	Explain how water collection instruments can be a source of mosquito breeding.	Cover water collection instruments every time

To clear mosquito breeding sites surrounding homesteads	Explain the importance of clearing water pits and bushes surrounding the homesteads	Perform regular cleaning activities at household level

To own a health insurance	Describe the importance of a health insurance in prompt health care-seeking	Participate in solidarity groups to enable regular contribution

To provide education on malaria symptoms	Describe common malaria symptoms	Identify common malaria symptoms

To promote early fever/malaria care-seeking (within 24 h)	Describe the importance of early care-seeking	Take a decision of seeking care promptly

To raise community awareness on the importance of diagnostic test before treatment	Describe the importance of a lab confirmed treatment for proper care and prevention of treatment resistance	Seek care at health facility (health centre/hospital)

To raise community awareness on the importance of malaria medication compliance	Describe the importance of treatment compliance to prevent disease relapse and treatment resistance	Adhere to the advice/treatment provided

To ensure proper training before implementation of larval source control	To provide knowledge on mosquito reproduction, malaria preventive measures and larval source control using biological substances	Attend onsite practical training

To adhere to the implementation plan	Discuss how larval source control will be implementedTo explain the use of reporting formats	Participate in actual implementation of larval source control


Company	Founded	Guidance and usage

EDAP TMS	1979	US

SonaCare Medical (previously US-HIFU, International HIFU and Focus Surgery)	1997	US

Chongqing HAIFU	1999	Both

China Medical	1999	US

Insightec	1999	MR

Image Guided Therapy	2001	MR—animals

Shanghai A&S	2001	Both

Mirabilis	2004	US

Theraclion	2004	US

Medsonic	2005	MR

Philips Healthcare	2005	MR

Supersonic Imagine	2005	Both

Profound	2008	MR

EyeTechCare	2008	Visual

Alpinion	2008	US

International Cardio Corporation	2009	US

Kona Medical	2009	US

Histosonic	2009	US

FUS instruments	2009	MR—animals

Acublate	2010	Both


 	Patients with anti-C1q autoantibodies	Patients without anti-C1q autoantibodies	r value(P value)	Patients with levels of C1q above 40.97 μg/ml	Patients with levels of C1q under 40.97 μg/ml	r value(P value)

Median(range)	Median(range)	Median(range)	Median(range)

Histopathological data

Activity Indices score	9(0,19)	7(0,16)	0.238(<0.001)	4(0,19)	9(0,19)	−0.327(<0.001)

Endocapillary hypercellularity	3(0,3)	2(0,3)	0.249(<0.001)	3(0,3)	1(0,3)	−0.337(<0.001)

Cellular crescents	2(0,6)	0(0,6)	0.167(0.013)	2(0,6)	0(0,6)	−0.182(0.007)

Karyorrhexis/fibrinoid necrosis	2(0,6)	0(0,4)	0.175(0.009)	2(0,6)	0(0,2)	−0.310(<0.001)

Subendothelial hyaline deposits	1(0,3)	1(0,3)	0.171(0.012)	1(0,3)	0(0,3)	−0.312(<0.001)

Interstitial inflammation	1(0,3)	1(0,3)	NS	1(0,3)	1(0,3)	NS

Leukocyte infiltration	1(0,3)	1(0,3)	0.159(0.019)	1(0,3)	1(0,3)	−0.246(<0.001)

Chronicity Indices score	2(0,9)	2(0,10)	NS	2(0,10)	2(0,9)	NS

Glomerular sclerosis	0(0,3)	0(0,3)	NS	0(0,3)	0(0,3)	0.146(0.031)

Fibrous crescents	0(0,3)	0(0,3)	NS	0(0,3)	0(0,2)	NS

Tubular atrophy	1(0,3)	1(0,3)	NS	1(0,3)	1(0,3)	NS

Interstitial fibrosis	1(0,3)	1(0,3)	NS	1(0,3)	1(0,3)	NS


Treatment type	IC50 values (μM)

on HepG2 cells	on A549 cells	on B16 cells

Duopafei®	0.96 ± 0.05	0.74 ± 0.02	0.72 ± 0.10

DTX-micelles	0.34 ± 0.02**	0.44 ± 0.05*	0.49 ± 0.08**

Blank micelles	12.84 ± 0.12	29.62 ± 1.02	13.79 ± 0.24


Characteristic	Round 1	Round 2

n-size	n-size

Response rate	46	22

Subjects

Male / Female	30/8	15/6

Location

Europe	18	9

Oceania	8	5

United States	5	4

Caribbean	2	1

Canada	1	-

Africa	1	1

South America	1	1

India	1	-

South East Asia	1	-

Discipline

Public health(incl.epidemiology)	21	11

Law (public health/social justice)	4	3

Geography	3	2

Agriculture	2	2

Transport	2	1

Policy	1	1

Nutrition	1	1

Environmental health	1	-

Planning (urban)	2	-

Economics	1	-

Sector

Academia	22	10

Not-for profit organisation	3	3

Government	12	7

Industry	1	1


	Crohn's disease	Healthy controls

Number (Male/Female)	16 (7/9)	16 (9/7)

Median [range] age (years)	42 [22-66]	33 [22-62]

Disease location	L1: 2	-

	L2: 6	-

	L3: 8	-

Previous bowel resection	6


Background characteristics	Percent	Selected independent variables	Percent

Maternal age (years)	27.3 ± 5.5*	Mode of delivery

15–24	38.0	Vaginal delivery	37.4

25–29	34.3	Vaginal delivery + episiotomy	41.3

30–34	16.8	C-section	21.3

35–51	11.0	Brought infant formula to delivery room	21.3

Maternal education	 	Experienced breastfeeding problems	10.6

Primary school or less	11.4	Received breastfeeding support from a family member

Secondary school	48.2	During pregnancy	31.8

High school	24.5	During first 3 days after delivery	31.9

College or higher	15.9	Received breastfeeding support from a health care provider

Female child	48.0	During pregnancy	44.1

Rural area of residence	83.3	During first 3 days after delivery	31.6

SES in quartiles	25.0	Exposure to infant feeding messages on TV in past 30 days

 	 	Saw only breastfeeding information	2.6

 	 	Saw only infant formula advertising	36.5

 	 	Saw both infant formula and breastfeeding advertising	43.3

 	 	Saw neither message	17.6


Characteristics	Frequency	%

Gender	Male	230	57.50

Female	170	42.50

Level of selfitis	Borderline	136	34.00

Acute	162	40.50

Chronic	102	25.50

Age	16 to 20 years	224	56.00

21 to 25 years	136	34.00

26 to 30 years	27	06.75

Above 30 years	13	03.25

Number of selfies taken per day	1 to 4 selfies	223	55.75

5 to 8 selfies	141	35.25

More than 8 selfies	36	09.00

Number of postings per day	None	136	34.00

At least one time to three times	162	40.50

More than three times	102	25.50


	Baseline	Outcomes

Measure		1 Month	3 Month	6 Month	12 Month

Demographic factors

Age, sex, race/ethnicity, educational attainment, employment status, martial/partner status, type of housing	X

Smoking history

Number of cigarettes per day, use of other tobacco products, use of electronic-cigarette, number of years smoking, prior quit attempt, smoker in household, home smoking policy	X

Nicotine dependence (time to first cigarette)	X

Previous cessation medication use	X

Importance in ability to quit	X

Confidence in ability to quit/stay quit	X	X	X	X

Tobacco abstinence status–self-report

Cigarette smoking status	X	X	X	X	X1

Non-cigarette tobacco use status	X	X	X	X	X1

Electronic-cigarette use	X	X	X	X	X1

Tobacco abstinence status–biochemical validation

Saliva cotinine or expired aired CO				X

Quit attempt (>24 hours)	X	X

Hospital admission or emergency room visit		X	X	X

Quality of life (EQ-5D)	X			X

Anxiety and depression symptoms (PHQ-4)	X	X	X	X

Alcohol use (AUDIT-C)	X			X

Other non-tobacco substance use	X

Satisfaction with IVR		X	X

Satisfaction with Quit Coach		X	X

Smoking during index hospital stay		X

Smoking cessation medication used after discharge		X	X	X

Smoking cessation counseling used after discharge		X	X	X

Other smoking cessation programs/resources used		X	X	X


Indicators Groups (IG)	Number of species per IG	Number of grid cells required to represent all species from each IG	Percentage of species represented by IG (%)	Land cost-effective by IG ($)

Brachycephalidae	35	9	63	30,929,850

Bufonidae	33	9	59	30,929,850

Cycloramphidae	41	11	69	37,803,150

Hylidae	184	26	69	89,352,900

Hylodidae	33	13	65	44,676,450

Leiuperidae	31	8	71	27,493,200

Leptodactylidae	30	11	65	37,803,150

Microhylidae	21	8	59	27,493,200


Biochemical category	Disease name	OMIM#	Gene(s)	Treatment	Effect	Level of evidence

Amino acids	PSAT deficiency	610992	PSAT1 (AR)	L-serine & +/−glycine supplements	Primary/targeting underlying pathophysiology	4

	PSPH deficiency (Serine deficiency)	614023	PSPH (AR)	L-serine & +/−glycine supplements	Primary/targeting underlying pathophysiology	4

Creatine	Arginine:glycine amidinotransferase (AGAT) deficiency	612718	GATM (AR)	Creatine supplements	Primary/targeting underlying pathophysiology	4

	Creatine transporter deficiency	300352	SLC6A8 (X-linked)	Creatine, glycine, arginine supplements	Primary/targeting underlying pathophysiology	4

Fatty acid oxidation	Carnitine palmitoyltransferase I deficiency	255120	CPT1A (AR)	Low-fat, high carbohydrate diet, avoid fasting, Medium Chain Triglyceride oil	Stablizilng/preventative treatment	4

Hyperhomocystinuria	Cobalamin deficiencies (e.g., C, D, E, F, G)	251110, 277400, 277410, 236270, 277380	MMACHC, MMADHC, MTRR, LMBRD1, MTR (AR)	Hydroxy-/cyanocobalamin (+/− diet restriction, betaine, B12)	Stabilizing/preventative treatment	4

Lipid storage (Leukodystrophy)	Cerebrotendinous xanthomatosis (CTX)	213700	CYP27A1 (AR)	Chenodeoxycholic acid	Stabilizing/preventative treatment	4

Organic acids	HMG-CoA lyase deficiency	246450	HMGCL (AR)	Protein restriction, avoid fasting, emergency regimen	Stabilizing/preventative treatment	4-5

	mHMG-CoA synthase deficiency	605911	HMGCS2 (AR)	Avoid fasting,emergency regimen, +/−dietary precursor restriction	Stabilizing/preventative treatment	5

	SCOT deficiency	245050	OXCT1 (AR)	Avoid fasting, protein restriction, emergency regimen	Stabilizing/preventative treatment	5

Urea cycle	Carbamoyl phosphate synthetase (CPS) deficiency	237300	CPS1 (AR)	Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)	Stabilizing/preventative treatment (primary/targeting underlying pathophysiology)	2b (4)

	Citrullinemia type I (ASS deficiency)	215700	ASS1 (AR)	Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)	Stabilizing/preventative treatment (primary/targeting underlying pathophysiology)	2b (4)

	N-acetyl-glutamate synthetase deficiency	237310	NAGS (AR)	Dietary protein restriction, arginine supplement, sodium benzoate, phenylbutyrate (Liver transplantation)	Stabilizing/preventative treatment	4


Average percent nucleotide identity (APNI)

Lactobacillus plantarum strains	WJL	WCFS1	ST-III	P-8	NC8	IPLA88	plantarumF

ZJ316	98.8	98.9	98.9	99.1	98.9	99.2	98.9

plantarumF	99.3	99.1	99.3	98.9	99.9	99.1	99.0

IPLA88	99.1	99.3	99.1	98.9	99.1

NC8	99.2	99.1	99.3	98.9

P-8	98.7	98.9	98.9

ST-III	99.6	99.1

WCFS1	98.9

Lactobacillus species	fructivoransF	fructivorans KCTC 3543	brevisF	brevis KB290	brevis EW	brevis ATCC 27305

brevis ATCC 14869	89.4	87.6	99.0	97.7	99.0	88.6

brevis ATCC 27305	87.0	85.3	91.3	92.2	90.0

brevis EW	89.8	88.8	98.7	97.6

brevis KB290	88.7	87.4	97.5

brevisF	89.7	88.3

fructivorans KCTC 3543	97.3


Name gene	Oligo direct	Oligo reverse	PCR conditions	Cycle number	GeneInfo identifier

18S	CTACCACATCCAAGGAAGGCA	TTTTTCGTCACTACCTCCCCG	95°C 15 sec	35	124517659

67°C 30 sec

ERK1	CTAAAGCCCTCCAACCTGCT	CAGCCCACAGACCAGATGT	95°C 15 sec	45	158138506

60°C 30 sec

STAT3	AAAGTCAGGTTGCTGGTCAAA	TGCCGTTGTTGGATTCTTC	95°C 15 sec	45	76253927

60°C 30 sec


Region	x	y	z	tpeak	pcorr(puncorr)

TEMPORALLY STABLE EFFECTS: POST-REAL rTMS > POST-SHAM rTMS

Haptic S2—crossmodal: VHi

No significant results

Haptic S2—unimodal: HHi

No significant results

Visual S2—crossmodal: HVi

No significant results

Visual S2—unimodal: VVi	>haptic S2

L FG	−33	−43	−26	2.70	0.051§	0.289§

L pIPS	−30	−64	55	2.91	0.034§	0.192§

LINEAR TIME DEPENDENT EFFECTS: POST-REAL rTMS > POST-SHAM rTMS

Haptic S2—crossmodal: VHi × time > visual S2	>visual S2

L parahippocampus / FG	−36	−16	−20	5.69	0.001	(<0.001)

R middle frontal gyrus	39	−4	61	5.46	0.004	0.014

R superior frontal gyrus	27	5	64	5.13	0.013	(<0.001)

R anterior parahippocampus	24	−1	−26	5.28	0.007

L pSTS/MTG	−48	−73	13	5.14	0.013	(<0.001)

R pSTS/MTG	42	−70	10	4.66	(<0.001)	(<0.001)

R LO	48	−73	−2	3.56	0.006§	0.024§

L aIPS	−36	−37	37	3.55	0.006§	0.002§

L pIPS	−21	−67	49	3.65	0.005§	0.001§

R pIPS	27	−61	46	2.99	0.026§	0.017§

Haptic S2—unimodal: HHi × time

No significant results

Visual S2—crossmodal: VHi × time

No significant results

Visual S2—unimodal: VVi × time

No significant results


Concentration (mg/mL)	The ratio of green and red fluorescence

Control	1.332 ± 0.045

0.005	1.420 ± 0.042∗∗

0.025	1.088 ± 0.037∗∗

0.1	0.801 ± 0.042∗∗

Positive control	0.477 ± 0.033∗∗


Sample	Metal organic line pressure (Torr)	Nanowire diameter (nm)	Gate-to-nanowire distance (nm)	Gate length (nm)	Source-to-drain distance (nm)

a	0	29	120	750	1,200

b	0.05	33	140	700	1,200

c	0.1	39	140	750	1,250

d	0.2	40	160	870	1,400

e	0.4	80	140	1,700	2,500


Genea	Reference (PubMedID)	Affected in	Peak length (bp)	Peak to transcription start site (bp)	Promoter class

Nos1	20645313	Hippocampus	334	-3,719	LCP

Map6	16624526	Hippocampus	169	-2,382	ICP

Drd5	11304828	Hippocampus	844	41	HCP

Cacna1c	23183239	Hippocampus	425	-3,692	LCP

Bdnf	16818862	Hippocampus	329	-492	ICP

Gsksb	18500637	Hippocampus	573	-1,042	HCP

Tf	18045615	Hippocampus	159	-3,020	LCP

Cnp	16389193	Hippocampus	464	1,198	HCP

Amacr	20875727	Hippocampus	558	164	HCP

Psen2	19232479	Hippocampus	249	620	LCP

Pax6	10376119	Hippocampus	341	326	ICP

Dlx1	18384059	Hippocampus	431	-2,043	HCP

Dlx1	18384059	Cerebellum	1,330	257	HCP

Cnp	16389193	Cerebellum	769	940	HCP

Psen2	19232479	Cerebellum	455	442	LCP

Pax6	10376119	Cerebellum	349	-3,481	ICP

Stx1a	15219469	Cerebellum	149	72	HCP

Drd5	11304828	Cerebellum	264	-169	HCP

Mmp9	20037727	Cerebellum	138	-325	LCP

Tnf	11244489	Cerebellum	269	49	LCP

Grin1	12679240	Cerebellum	264	-1,595	HCP

Tf	18045615	Cerebellum	749	-1,704	LCP

Dlg4	21151988	Cerebellum	134	-1,459	LCP

Amacr	20875727	Cerebellum	138	-48	HCP

Dao	19685198	Cerebellum	287	-2,385	LCP

Dlx1	18384059	Liver	171	-2,993	HCP

Cnp	16389193	Liver	644	-2,644	HCP

Sod2	15193990	Liver	550	594	HCP

Drd5	11304828	Liver	369	-316	HCP

Il6	20393813	Liver	789	-3,030	LCP

Comt	11381111	Liver	638	-3,542	HCP

Apoe	14674716	Liver	2,158	-1,223	LCP

Drd2	18829695	Liver	257	-91	HCP

Nos1	20645313	Liver	348	172	LCP

Drd1	20127886	Liver	540	739	LCP


Mentorship demographics	No. (%)

	(N=389 with mentor)

	Male	Female	p	Fisher Exact Test

Department of mentor

Same department	255 (91.1)	95 (91.3)	0.93	1.0

Another department	25 (8.9)	9 (8.7)

Position of mentor

Dept. Chair / Professor	67 (23.9)	22 (21.4)	0.62	0.66

Associate Prof.	59 (21.1)	27 (26.2)

Lecturer	58 (20.7)	19 (18.4)

Assistant Prof.	80 (28.6)	32 (31.1)

Other	16 (5.7)	3 (2.9)

Mentor assignment initiated by

Mentor	242 (87.7)	84 (88.4)	<0.01	0.01

Mentee	34 (12.3)	11 (11.6)

Other	4 (1.4)	8 (7.8)

Mentoring Meeting Frequency

Every month or more	213 (76.1)	83 (79.8)	0.44	0.50

Other (combining all other categories)	67 (23.9)	21 (20.2)

Satisfaction with Mentoring

Very satisfied/ A little satisfied	212 (75.7)	75 (72.8)	0.56	0.60

Not Satisfied\Neutral	68 (24.3)	28 (27.2)


Characteristics

Body mass index 	>30 Kg/m2	10 (8.4%)

Onset of labour	Spontaneous	87 (73.1%)

Induced	21 (17.6%)

Augmented	11 (9.2%)

Use of oxytocin	None	44 (37.0%)

Yes	75 (63.0%)

<4 cm = 19, 4–7 cm = 30, 8–10 cm = 26

Position of fetal head	Right/left/direct occipitoanterior	34 (28.5%)

Right//left/direct occipitoposterior	40 (33.6%)

Occipitotransverse	43 (36.1%)

Others	2 (1.8%)

Station of the fetal head (distance of the leading bony point of fetal skull below the ischial spines, measured in centimeters)	Above −1	1

−1	2

0	68

+1	48

+2	2

Fetal size	Mean 3588 g (2365 g–4840 g)

Operator experience 	Trainee <5 years	13 (10.9%)

Trainee 6-7 years	82 (68.9%)

Consultant (>8 years)	24 (20.2%)

Time of decision to perform operative vaginal birth 	0800–1700	36 (30.3%)

1701–2000	11 (9.2%)

2001–0759	72 (60.5%)

Length of second stage of labour (in cases where the indication was “failure to progress”)	<3 hr	5.2%

3.01–≤4 hr	14.4%

≥4.01 hr	80.4%


N	Complications	Additional comments	Surgical procedure

5	Equipment failure	Loose halter	Exploratory laparotomy

Tail hair broke	Sarcoid removal

Tail hair broke	Tooth extraction

Tail rope slipped off	Castration

Facial paralysis	Wound closure

4	Poor quality	Fell down after standing	Arthroscopy

Several attempts to stand	Arthroscopy

Lost shoe and broke hoof wall	Sarcoid removal

None	Arthroscopy

3	Long recovery	None	Tumour removal

None	Exploratory laparotomy

Cardiac arrest. Resuscitated	Arthroscopy

2	Excitation	Respiratory problem	Neurectomy

Wound to coronary band.	Desmotomy/Neurectomy

2	Myopathy	None	Exploratory laparotomy

None	Metatarsal fracture repair

1	Restless	Dog–sitting position	Eye surgery

1	Hindlimb Weakness	None	Mandibular fracture


Variables	SCA2 patients	Preclinical carriers	Healthy controls

	ICC	p	H	ICC	p	H	ICC	p	H

Saccade velocity (°/s)	0.47	0.002	~94%	0.19	0.222	NA	0.136	0.289	NA

Saccade accuracy (%)	0.16	0.170	NA	0.20	0.208	NA	0.013	0.473	NA

Saccade latency (ms)	0.16	0.170	NA	0.13	0.294	NA	0.286	0.121	NA


Gene identifier	Gene label	Description	Protein identifier

http://bio2rdf.org/sgd:S000004688	YMR083W	Mitochondrial alcohol dehydrogenase isozyme III	http://bio2rdf.org/sgd:S000004688gp

http://bio2rdf.org/sgd:S000000349	YBR145W	Alcohol dehydrogenase isoenzyme V	http://bio2rdf.org/sgd:S000000349gp

http://bio2rdf.org/sgd:S000002624	YDR216W	Carbon source-responsive zinc-finger transcription factor	http://bio2rdf.org/sgd:S000002624gp

http://bio2rdf.org/sgd:S000000819	YER017C	Component of the mitochondrial inner membrane m-AAA protease	http://bio2rdf.org/sgd:S000000819gp

http://bio2rdf.org/sgd:S000001306	YIL044C	ADP-ribosylation factor (ARF) GTPase activating protein (GAP) effector	http://bio2rdf.org/sgd:S000001306gp


Histotypea	Cell lineb	IC50 μM (± SE)c,f	Genetic alterationd	Doubling time (hours)e,f

RHABDOMYOSARCOMA	RD/18	6.8 (± 2.1)	Altered 11p15.5 chromosome	22 ± 0.1

 	SJ-RH4	5.6 (± 1.3)	(2;13)(q35;q14) PAX3 FKHR	25 ± 1.2

 	SJ-RH30	9.9 (± 2.7)	(2;13)(q35;q14) PAX3 FKHR	26 ± 1.0

OSTEOSARCOMA	IOR/OS10	5.5 (± 1.3)	Complex Karyotype	30.4 ± 2.6

 	IOR/OS9	8.6 (± 1.8)	Complex Karyotype	44.5 ± 2.4

 	Saos-2	11.9 (± 3.1)	Complex Karyotype	36.1 ± 4.4

 	Saos-2/DX580	39.3 (± 2.6)	Complex Karyotype	75.6 ± 5.7

 	Saos-2/CDDP6ug	43.3 (± 6.8)	Complex Karyotype	44.3 ± 4.1

 	U-2OS	12.5 (± 0.7)	Complex Karyotype	18.3 ± 0.2

 	U-2OS/DX580	16.5 (± 0.4)	Complex Karyotype	45.3 ± 4.7

 	U-2OS/CDDP4ug	56.1 (± 1.4)	Complex Karyotype	38.6 ± 4.1

EWING SARCOMA	6647	3.1 (± 1.4)	t(11;22)(q24;q12) EWSR1-FLI1 TYPE II	29 ± 2.3

 	LAP-35	11.6 (± 0.7)	t(11;22)(q24;q12) EWSR1-FLI1 TYPE II	48.6 ± 4.2

 	SK-N-MC	3.9 (± 0.5)	t(11;22)(q24;q12) EWSR1-FLI1 TYPE I	26.9 ± 0.5

 	TC-71	2.6 (± 1.4)	t(11;22)(q24;q12) EWSR1-FLI1 TYPE I	14.9 ± 1.4

 	TC/DOXO8	5.0 (± 0.1)	t(11;22)(q24;q12) EWSR1-FLI1 TYPE I	22.6 ± 2.8

h-MSC	MES1	>50	n.d.	n.d.

 	MES2	>50	n.d.	n.d.

 	DP-15	>50	n.d.	n.d.


Country	Paliperidone (maximum), %

Austria	0.04

Belgium	4.8

Bury PCT	0.07

Ireland (GMS population)	1.01

Scotland	0.03

Spain (Catalonia)	3.99

Sweden	1.5


Walking Speed (Steps/min)	Actual ZVI Number	Detected ZVI Number

Fixed Threshold Method	Adaptive ZVI Detection Algorithm

80	100	102	100

100	100	100	100

120	100	94	100


	Total Epidemic Size	Days to Epidemic Season Peak	Length of Epidemic Season

Regression Intercept (S.E.)	321.0 (417)	87.5 (13.5)	192.3 (24.0)

Regression Slope (S.E.)	15383 (7175)	-255.3 (233)	-659 (413)

Regression Model p-value	0.08	0.32	0.17

R2	0.48	0.19	0.20

Root Mean Square Error	17.6	3.2	4.2

Mean of Absolute % Error	16	11	8


	Mean	Median	Min	Max	Range*1	SD*2

Referral rate of participating GPs	0.68	0.65	0.53	0.88	0.35	0.11

Referral rate of non-participating GPs	0.74	0.76	0.47	1.00	0.53	0.15


Molecular Class	Number of Molecules Altered Within Each Pathway

Nitrite (80 mg/day)

Glycerophospholipids	13

Sphingolipids	2

Glycerolipids	1

Fatty Acyls	3

Carbohydrates and Carbohydrate Conjugates	1

Carboxylic Acids and Derivatives	2

Imidazole Ribonucleosides and Ribonucleotides	1

Pyridines and Derivatives	1

Peptide Hormones	1

Unknown	20

Nitrite (160 mg/day)

Glycerophospholipids	9

Sphingolipids	2

Carboxylic Acids and Derivatives	2

Polypeptide	1

Pyridines and Derivatives	1

Unknown	18


 	 	Total number of hits	Standard articles retrieved

Keyword search (basic topic + sex differences search)	Stroke	301	33/94

 (stroke AND sex difference*); filters: human, Englishor(diabetes AND sex difference*); filters: human, English	Diabetes	539	23/95

TTUHSC SGSH PubMed search tool: Basic	Stroke	566	50/94

 (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR gender based) AND (gender[ti] OR sex[ti]); filters: human, EnglishTotal number of hits at the time of validation: 21,315	Diabetes	1027	62/95

TTUHSC SGSH PubMed search tool: Expanded	Stroke	1623	77/94

 (sex based OR sex factors OR sex distribution OR sex characteristics OR sex dimorphism OR gender difference* OR female) AND (gender[ti] OR sex[ti] OR women[ti] OR female[ti]); filters: human, EnglishTotal number of hits at the time of validation: 97,972	Diabetes	5569	81/95


Dietary change	Epigenetic effects	Outcome	Species	Reference

Vitamin B12, folate and methionine deficient	DNA methylation	Hypomethylation in methyl-deficient diet	Sheep	Sinclair et al., 2007

Betaine supplementation	DNA methylation	Increased global measures of DNA methylation	Chicks	Hu et al., 2015

Betaine supplementation	DNA methylation, Histone modification	PEPCK1 hypomethylated and enriched for H3K27me3. PEPCK2 and FBP1 hypermethylated and enriched for H3K4me3	Neonatal Piglets	Cai et al., 2014

Zinc supplementation	DNA methylation	Hypomethylation and increased expression of gene A20	Hens	Li et al., 2015

Variable zinc levels	DNA methylation	Hypermethylation in regulatory regions of gene ZIP4	Piglets	Karweina et al., 2015

Restrictive feeding	Histone modification	Increased global measures of H3K9 acetylation and reduction in H3K9me3 in IUGR pigs subjected to restrictive feeding	Pigs	Nebendahl et al., 2016

Folic acid supplementation	DNA methylation	Hypermethylation in IUGR piglets with folic acid supplementation compared to piglets fed control diet	Pigs	Jing-bo et al., 2013

Maternal protein insufficiency	DNA methylation	Hypomethylation in POMC and GR in the sheep brain	Sheep	Begum et al., 2012

Methylating micronutrients	DNA methylation	IYD gene differentially methylated between groups of pigs with extreme obesity related phenotypes	Pigs	Braunschweig et al., 2012


Region	Methylation status	# CpG in	# of molecules detected	% of total

MseI frag.	Ampl-icon	Exp 1	Exp 2	Exp 3	Exp 4

1	unmethylated	0	0	1	0			3.0

Hha-methylated	2	0	0	0

HpaII-methylated	11	2	1	0			3.0

Fully methylated	54	11	15	16			93.9

2	unmethylated	0	0	1	1			11.8

Hha-methylated	0	0	0	0

HpaII-methylated	2	1	1	0			5.9

Fully methylated	12	11	6	8			82.4

3	unmethylated	0	0	15	14	7	5	80.4

Hha-methylated	3	2	0	0	0	0	0

HpaII-methylated	3	1	0	0	0	0	0

Fully methylated	23	17	0	6	1	3	19.6


			Trial I (unselective supplementation in all mothers from week 18)		Trial II (selective supplementation in nutritionally at risk mothers from week 28)

Trial Group			Protein, Carbohydrate and Vitamins1	Carbohydrate and vitamins2	Vitamins only3	p7	Protein, Carbohydrate and Vitamins4	Carbohydrate and vitamins5	Vitamins only6	p7

	Mean Birthweight kg	Original trial (n)	3.01 ± 0.06 (47)	3.02 ± 0.07 (50)	3.06 ± 0.07 (45)	0.87	3.34 ± 0.14 (14)	2.95 ± 0.15 (17)	3.01 ± 0.07 (14)	0.09

		Traced participants (n) 	2.97 ± 0.07 (40)	2.96 ± 0.07 (41)	3.07 ± 0.08 (38)	0.53	3.34 ± 0.14 (14)	2.96 ± 0.17 (15)	3.01 ± 0.07 (13)	0.15

		Assessed in clinic (n)8	3.11 ± 0.09 (21)	2.95 ± 0.08 (23)	3.08 ± 0.12 (21)	0.48	3.23 ± 0.13 (8)	3.42 ± 0.15 (4)	3.03 ± 0.11 (8)	0.18


Factors	Domains	Major themes and their dimensions

Enabling	Availability of support	Formal support

		 Conflict with centre's hours of operation

		 Lack of an effective appointment reminder system

		 Proximity to the centre

		 Difficulties in locating the centre

		 Regular physician visits

		Informal support

		 Dependent on family assistance

		 Family responsibilities

	Familiarity with resources	Diabetes education centre and its services

		 Familiarity with DEC services

Predisposing	Self-efficacy	Diabetes self-management

		 Sufficient amount of information

		 Adherent to self-management activities

		 Non-adherent to self-management activities

	Attitudes	Diabetes education

		 Level of priority

		 Apathy

	Co-morbidity	Competing health conditions

Need	Perceived/evaluated	Disease severity

		 Patient judgment of severity

		 Physician judgment of severity


Outcome	RR	95% Confidence interval	p-value

Total cesarean SSIs	1.10	0.58–2.08	0.765

Cesarean incisional SSIs	0.23	0.03–1.78	0.158

Cesarean organ/space SSIs	1.62	0.83–3.18	0.160


Year	Milestone	References

1994	Discovery of serum autoantibodies recognizing the nuclear DFS-IIF pattern in patients with interstitial cystitis	[4]

1997	Partial cDNA sequence encoding the autoepitope region of the DFS70 autoantigen deposited in GenBank under accession number U94319	[3]

1998	Discovery of transcription co-activator p75, later known to be identical to DFS70 and LEDGFp75	[13]

1999	Discovery of LEDGFp75 using autoantibodies from a cataract patient	[14]

2000	Characterization of DFS70 using autoantibodies from patients with atopic dermatitis and other conditions, and initial observation that these autoantibodies are present at low frequencies in SARD patients	[3]

2001–2002	Demonstration that DFS70/LEDGFp75 is cleaved during cell death into fragments that are recognized by autoantibodies	[32, 98]

2003–2004	Discovery of DFS70/LEDGFp75 as a key cellular co-factor of HIV-1 integration	[17-20]

2004	Initial observation that anti-DFS70/LEDGFp75 autoantibodies are present in apparently healthy individuals	[125]

2004	Identification of a major B cell autoepitope in the carboxy-terminal region of DFS70/LEDGFp75	[62]

2005	Identification of DFS70/LEDGFp75 as a tumor associated autoantigen	[99]

2005	Demonstration that anti-DFS70/LEDGFp75 autoantibodies are a very common occurrence in human sera screened for ANAs by HEp-2 IIF in a clinical laboratory and can be detected in a wide array of immunological conditions	[7]

2008	Observation that patients producing anti-DFS70/LEDGFp75 autoantibodies as the only serum ANA pattern are rarely diagnosed with SARD	[28]

2011–2012	Description of anti-DFS70/LEDGFp75 autoantibodies as a potential exclusion biomarker for SARD	[26, 107]

2012	Development of a highly specific ANA test based on immunoadsorption of anti-DFS70/LEDGFp75 autoantibodies	[5]

2012	Introduction of a new algorithm for ANA testing that considers anti-DFS70/LEDGFp75 autoantibodies	[6]

2013	First commercially available diagnostic test (Inova Diagnostics) for the detection of anti-DFS70/ LEDGFp75 antibodies	N/A


Characteristicb	Cases	Controls

	Adult Glioma Study (n = 622)	The Cancer Genome Atlas (n = 70)	Adult Glioma Study (n = 602)	Illumina iControls (n = 3,390)

Age	55 ± 0.5	54 ± 1.7	56 ± 0.6	29 ± 0.4

GENDER

Male	398 (64%)	40 (57%)	319 (53%)	1,254 (37%)

Female	224 (36%)	30 (43%)	283 (47%)	2,136 (63%)

TUMOR SUBTYPE

Grade III	97 (16%)	0 (0%)	–	–

Grade IV	525 (84%)	70 (100%)	–	–


	Components	East-West	North-South	Vertical

RMS

Relative positioning	Code (m)	0.66	1.07	1.80

Carrier-phase (cm)	1.35	2.49	3.15

Velocity estimation (cm/s)	1.35	1.70	3.23


Disease category	# of specific genes	Total genes	% of specific genes

ASD	189	321	69.8

FASD	27	106	25.5

CP	23	124	22.1


Metabolite	Gene involved in biosynthesis	Locus number	Biological Evidence	Reference

Pyoverdine	pvdSL; pvdIJKDEONMP; fpvI; pvdA	PSF113_1749-1750; PSF113_1836-1847; PSF113_1856-1860	Yes	[2]

Pyridine-2,6-bis-thiocarboxylic acid (PDTC)	pdtCKPELMFGHIJON	PSF113_2605-2618	No

2,4 diacetyl-phloroglucinol (DAPG)	phlIEDBCAFGH	PSF113_2457-2464	Yes	[4]

Hydrogen cyanide (HCN)	hcnABC	PSF113_2367-2369	Yes	[83]

Putative Lankacidin	lkcABCDEFGJ; pqqFABCDEG	PSF113_3657-3666; PSF113_5383-5388	No

PKS-like metabolite	 	PSF113_3045-3053	No


Parameter	P	Odds ratio (OR)	95% confidence interval (CI)

Maternal age	0.846	0.995	0.943–1.050

Multiparity	0.293	0.751	0.459–1.235

Previous uterine surgery (including myomectomy, caesarean section, reconstructive surgery, or septum resection)	0.490	1.132	0.718–1.784

BMI

 Extremely low (under 18.5) 	0.402	0.538	0.126–2.290

 High (above 30)	0.544	0.764	0.320–1.823

Supernumerary embryos developed in IVF cycle	0.275	1.269	0.827–1.946

Transfer of 2 embryos	0.043	1.952	0.020–3.735

Spontaneous cycle ET	0.064	0.417	0.150–1.164


	Abrupt	Gradual 1	Gradual 2	All treatments

Randomized, n	41	40	42	123

Safety population, n	40	39	42	121

Completed, %	75	72	88	79

Discontinued, %	25	28	12	21

 Adverse event	5	15	5	8

 Withdrew consent	10	8	0	6

 Insufficient response	5	0	0	2

 Lost to follow-up	0	3	2	2

 Noncompliance	0	0	2	1

 Other	5	3	2	2


Cat Demographics	Free Cats n = 73 (%)	Normal-Fee Cats n = 78 (%)

Cat Ages

Age range	1–16 years	1–14 years

Age mean	4 years	3 years

Cat Sex

TOTAL females	52 (71)	57 (73)

Female adults	46 (63)	54 (69)

Female matures	6 (8)	3 (4)

TOTAL males	21 (29)	21 (27)

Male adults	16 (22)	19 (24)

Male matures	5 (7)	2 (3)

Pelage Varieties

Blacks and Browns	9 (12)	6 (8)

Calicos and Tortoiseshells	8 (11)	17 (22)

Brindles and Gingers	9 (12)	4 (5)

Greys and Whites	9 (12)	13 (17)

Piebalds	12 (16)	13 (17)

Tabbies	26 (36)	25 (32)

Cat Fate

Alive and Retained by original adopter	68 (93)	75 (96)

1 Dead	3 (4)	0 (0)

2 Returned to shelter	0 (0)	3 (4)

3 Rehomed privately	1 (1)	0 (0)

4 Ran away	1 (1)	0 (0)


 	Bariatric Surgery (N = 34)	Lifestyle Intervention (N = 34)	P

Age (yrs)	43.3 ± 9.4	40.9 ± 10.5	0.33

% Female	76.5	76.5	1.00

% Race	 	 	0.25

 White	79.4	70.6

 African-American	5.9	14.7

 American Indian/Alaskan Native	2.9	0.0

 Native Hawaiian/Other Pacific Islander	2.9	0.0

 Other	8.8	5.9

 Don’t know	0.0	8.8

% Ethnicity	 	 	1.00

 Non-Hispanic	91.2	91.2

 Hispanic	8.8	8.8

BMI (kg/m2)	46.2 ± 7.8	45.0 ± 4.9	0.49

Weight (kg)	129.9 ± 27.6	127.7 ± 19.6	0.71


Registered indications	Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with

	-Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41]

	- Acquired hemophilia [42]

	- Congenital factor VII deficiency [43]

	- Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44]

Potential indications	Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46]

	Treatment of bleedings after all conventional measures have failed in patients with

	- Chronic liver disease [47]

	- Thrombocytopathy [48]

	- Platelet-refractory thrombopenia [49]

	- Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4)

	- Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50]


Domain/outcome	Questionnaire/items	Assessment time point	Reference

Primary Outcome	 	t1	t2	t3	t4

Physical functioning	Hannover Functional Ability Questionnaire (FfbH-R)	x	x	x	x	[51]

Secondary Outcomes

Pain

 Pain intensity	Numeric Rating Scale (NRS)	x	x	x	x	[52]

 Pain status	Graded Chronic Pain Status (GCPS)	x	x	x	x	[53]

Physical activity	Freiburg questionnaire on physical activity (FFkA)	x	 	x	x	[54]

Emotional functioning

 Depression	Patient Health Questionnaire (PHQ-D)	x	x	x	x	[55]

 Anxiety	Generalized anxiety disorder 7-item scale (GAD-7)	x	x	x	x	[56]

Health related quality of life	Short-Form-12 (SF-12)	x	x	x	x	[57]

Stress	Perceived Stress Scale (PSS)	x	x	x	x	[58]

Pain related cognitions, emotions and behavior

 Cognitive and behavioral pain coping strategies	Pain Management Questionnaire (FESV)	x	x	x	x	[59]

 Fear-avoidance and endurance-related responses to pain	Avoidance-Endurance Questionnaire (AEQ)	x	x	x	x	[60]

 Pain related fear	Tampa Scale for Kinesiophobia (TSK)	x	x	x	x	[61,62]

Motivational and volitional determinants of physical activity

 	risk perception (3 items), self-efficacy (3 items), outcome expectancies (11items), experiences with physical activity (5 items), self-concordance (12 items), intention (7 items), action (4 items) and coping (4 items) planning, action control (6 items)	x	x	x	x	[63-67]

 Stage of change algorithm for physical activity	two Items (Have you performed moderate physical for 30 minutes or longer on a minimum of 3 days per week? and "Since when are you as regularly active as you are now?"; possible answers: 1. Question: no, and I don’t intend to do so; no, but I am thinking about doing so; no, but I have the strong intention to do so; yes, but it is difficult to me; yes, and it is easy for me; 2. Question: open)	x	x	x	x	[68,69]

Attitudes towards performing physical activity	modified Version of Short-Questionnaire to measure cognitive and affective attitudes toward sports activities	x	x	x	x	[70]

Treatment satisfactions with exercise therapy	18 items (e.g. “I would recommend the exercise therapy other patients.” measured by using a six-point ordinal scale with 1= “absolutely agree”, 6=“absolutely disagree”; e.g. “The time extent of the exercise therapy, I perceived as...” measured by using a five-point ordinal scale with 1=“far too high“, 5=“far too low“; e.g. “Overall, how do you rate the exercise therapy?” measured by using a six-point ordinal scale with 1= “very satisfied”, 6=not “satisfied at all”)	 	x	 	 	self-designed

Treatment satisfactions with the rehabilitation process	five items (e.g. “Overall, how do you rate the rehabilitation process?”) measured by using a ten-point ordinal scale (1= “very poor”, 10 = „excellent“)	 	x	 	 	self-designed

Others

 Demographic characteristics	sex, age, height, nationality, marital status, education, monthly income, weight, self-reported work status	x	 	 	 	[71]

 Social medical characteristics	a) self-reported low back pain related sick leave, use of health care services, medication use for the last six month and self-reported plan to apply for retirement, severe disabilities	x	 	 	 	[71]

 	b) diagnosis, work status and physical capability taken from the hospital discharge report	 	x

 Aftercare	a) aftercare recommendations taken from the hospital discharge report	 	x	 	 	self-designed

b) self-designed; five items (e.g. “Have you participated in the last twelve months in a medically prescribed exercise therapy to rehabilitation aftercare?” with the option to answer yes/no)	 	 	 	x

Job satisfaction	scale on job satisfaction (IRES-3)	 	 	x	x	[72]


	Incremental Difference: Complete Banvs.Current Legislation	Incremental Difference: Optimistic Case	Incremental Difference: Worst Case

Gross Intervention Costs (C)	3,994,645	1,996,438	5,067,102

AMI Treatment Costs Saved (T)	40,051,602	237,927,598	1,626,740

All Tobacco-Attributable Treatment Costs Saved (T)	99,609,250	946,905,837	2,527,779

Net Costs (AMI Treatment) *(C-T)	–36,056,957	–235,931,160	3,440,362

Net Costs (All Tobacco-Attributable Disease Treatment) * (C-T)	–95,614,605	–944,909,399	2,539,322

AMI Cases Averted (A)	17,478	53,361	13,109

Smokers Quitting (Q)	221,154	385,100	46,060

Life Years Gained (L)	437,589	891,945	45,268

Incremental Cost-Effectiveness Ratios

Cost per LY Gained (C-T)/(L)	Cost Saving	Cost Saving	56 (USD) Highly Cost-Effective

Cost per LY Gained w/out Medical Treatment Saved (C/L)	9.13 (USD) Highly Cost-Effective	2.24(USD) Highly Cost-Effective	112 (USD) Highly Cost-Effective

Cost per AMI Case Averted (C-T)/A	Cost Saving	Cost Saving	262 (USD) Highly Cost-Effective

Cost per AMI Case Averted w/out Medical Treatment Saved (C/A)	229 (USD) Highly Cost-Effective	37 (USD) Highly Cost-Effective	387 (USD) Highly Cost-Effective


	T. trichiura Uganda	T. trichiura China	T. trichiura Ecuador

T. trichiura Uganda		0.979**	0.932***

T. trichiura China	0.984**		0.551*

T. trichiura Ecuador	0.967***	0.778*


		Aurora A and p27 expression	P

		2H	1H1L	2L

Sex

Male	63	54	7	2	0.191

Female	17	15	2	0

Age (years)

<60	27	22	5	0	0.071

>=60	53	47	6	0

Tumor volume (cm3)

<=5	46	40	6	0	0.203

>5	34	29	3	2

Tumor location

Up	19	15	4	0	0.687

Middle	22	19	3	0

Down	39	35	4	0

Pathological grade

II	26	20	6	0	0.991

II–III	25	25	0	0

III	29	24	3	2

Invasion stage

Mucosal and submucosal	1	1	0	0	0.372

Muscular layer	8	7	1	0

Serous membrane and outmembrane	71	61	8	2

Lymph node metastasis

0	17	16	1	0	0.510

1–6	36	29	7	0

>=7	27	24	3	0

TNM stage

I	5	5	0	0	0.031

II	22	19	3	0

III	46	41	3	2

IV	7	4	3	0

Total	80				80


Inhalation repeats	PIF cut-off value (L/min)	Sensitivity (%)	Specificity (%)	AUC	Positive predictive value (%)	Negative predictive value (%)

I	140	84	53	0.69	81	59

II	120	86	69	0.83	69	86

III	100	89	76	0.89	59	95

IV	100	87	71	0.86	48	95


Observation	Genotype	Males	Females

Body weight (g)	WT	31.5 ± 18.8	20.3 ± 0.9

	TG	25.5 ± 1.7*	22.2 ± 0.9

Body length (mm)	WT	92.8 ± 0.9	86.6 ± 0.5

	TG	89.4 ± 1.0*	87.8 ± 1.1

Grip strength (score 0–4)	WT	2.4 ± 0.2	1.0 ± 0

	TG	0.8 ± 0.2**	1.6 ± 0.2

Wire maneuver (score 0–4)	WT	1.4 ± 0.2	2.8 ± 0.5

	TG	4.0 ± 0***	2.0 ± 0.6

Tail elevation (score 0–2)	WT	2.0 ± 0	1.4 ± 0.2

	TG	1.2 ± 0.2*	1.2 ± 0.2


Sample ID	Tumor type	Tumor cell (%)	Sequencing depth (x)	JAK2 p.V617F allele fraction (%)	Co-occurring mutation (allele fraction %)

592	Non-small cell carcinoma	30	1999	8.2	KRAS p.G12V (17.2)

664	Adenocarcinoma with squamous features	50	1996	7	BRAF p.V600E (27.3)

717	Adenocarcinoma	40	1273	2	-

915	Favoring adenocarcinoma	60	1539	2.1	EGFR exon19 del (52.1)

1182	Adenocarcinoma	40	1997	2.4	BRAF p.V600E (10.4)

1200	Mucinous adenocarcinoma	10	1422	10.5	KRAS p.G12V (4.8)

1527	Adenocarcinoma	30	1997	10.8	-

1588	Adenocarcinoma, acinar type	20	892	6.5	-

1825	Adenocarcinoma with mucinous features	30	1998	13.4	KRAS p.G12C (25.4)


Category	Gene	Homolog	WT1	WT2	MT	Description	Reference

Iron transport	Ftr1	HMPREF1120_04509	6.76	64.20	53.35	High-affinity iron transporter	Stearman et al., 1996

	Fet3	HMPREF1120_04510		42.88	23.29	Ferrooxidoreductase Fet3

	SidF	HMPREF1120_01438	4.55	3.58	5.95	Acetyl CoA:N6-hydroxylysine acetyl transferase	Chen et al., 2014

	SidD	HMPREF1120_01440	8.74	4.41	6.92	Nonribosomal peptide synthase Pes1

	SidA	HMPREF1120_07635	7.34	4.25	8.73	L-ornithine N5-oxygenase

	SidC	HMPREF1120_07636	2.46			Nonribosomal siderophore peptide synthase SidC

	Sit1	HMPREF1120_01434	4.47	7.10		MFS transporter, SIT family, siderophore-iron: H+ symporter	Heymann et al., 2000; Petris, 2004

		HMPREF1120_02555	7.07	5.76	7.22	MFS transporter, SIT family, siderophore-iron: H+ symporter

		HMPREF1120_07838	14.26	16.02	10.33	MFS transporter, SIT family, siderophore-iron: H+ symporter

Copper pransport	Crt	HMPREF1120_00028			4.74	Copper transporter family	Petris, 2004

		HMPREF1120_05417			7.31	Copper transporter family

		HMPREF1120_00028			4.72	Copper transporter

	Atx1	HMPREF1120_03801			4.78	Heavy metal associated domain, Cu receptor	Lin et al., 1997


Structural themes	Referential themes

To be prepared for emergency situations	Focus on overview of accident site and patient and on need of feedback

To observe the situation -Ready to act Confirmation and Validation of one’s knowledge

Confidence in one’s own leadership	Focus on handling leadership.

Responsibility of leadership in emergency situations and

Combining theory and practice

Developing professional knowledge	Focus on how the work strategy changes based on the competency of the colleague and the need for competence and skills development.

 	Lack of a prehospital work strategy, Supporting novices, - Being alone,Being familiar with the equipment, Seeking new knowledge and Practicing critical scenarios


 Variable	Healthy controls (n = 17)	Individuals with schizophrenia (n = 16)	t (df = 31)*	P value

Age (years)	43.65 ± 11.32	48.69 ±8.38	−1.446	.158

Gender	3 females; 14 males	4 females; 12 males	NA	NA

Education (years)	15.47± 1.81	13.00 ± 2.25	3.487	.001

Subject's SES	2.23± 1.01	3.63 1.41	−2.992	.006

Parental SES	2.54 ± 0.88	3.13 ± 1.45	−1.275	.213

Onset age (years)	NA	30.23 ± 11.95	NA	NA

Duration (years)	NA	17.15± 11.32	NA	NA

Chlorpromazine equivalent (mg)	NA	381.13 ± 247.18	NA	NA

Medication type	NA	First generation = 3 Second generation = 9	NA	NA

Positive scale PANSS	NA	23.87 ±9.41	NA	NA

Negative scale PANSS	NA	22.33± 9.56	NA	NA

General psychopathology PANSS	NA	43.00 ± 14.64	NA	NA

Total psychopathology PANSS	NA	89.20 ± 30.17	NA	NA


Flavonoid class	Molecular Weight	Glycosylation	Metabolic conversion	Colonic microflora

General	Decreases bioavailability	Generally removed	Major factor in bioavailability; can take place in small intestine, liver and colon; usually to glucuronides but also sulphation and methylation [39]; facilitates urinary and biliary excretion [39].	Influence availability; catabolize compounds to low molecular weight compounds that are readily absorbed [58].

Flavan-3-ols (monomeric)			Major bioactive forms: conjugates of epicatechin [41]; catechin: methyl, sulfate and glucuronic acid conjugates; epicatechin: mainly to sulfate conjugates, no glucuronidation [41].

Proanthocyanidins	Decreases bioavailability [40].		Major bioactive forms: conjugates of epicatechin [41]; oligomeric procyanidins can absorb in small intestine [51].	Influences polymeric proanthocyanidin degradation [50].

Flavonols		Sugars and their position affects bioavailability [44].	Potentially active metabolites: glucuronides [44].	Facilitates glucuronidation [60].

Anthocyanins	Anthocyanin derivatives (flavan-3-ol-anthocyanin dimer) can potentially be absorbed with less efficiency [47].	Sometimes found with sugars intact in circulation [55].	Major intestinal metabolites: glucuronide and sulfate conjugates of protocatechuic acid and phloroglucinaldehyde [46]; anthocyanin derivatives metabolically more resistant than parent compounds [47].

Isoflavones		Aglycone more bioavailable; possible deglycosylation prior hepatic metabolism [48].		Metabolize daidzein to equol [58].

Flavanones		Rapid absorption, low bioavailability [49].		Extensive first-pass metabolism partly by intestinal bacteria degraded into phenolic compounds [49].


#	Name	Tag/Fusion protein, positiona and lengthb	TEV protease cleavage site	Mode of expression	EAEA repeat	Selection markerc	Plasmid size (bp)

1	PPpRSFC	–	–	–	NA	Intracellular	NA	Zeocin	4,840

2	pPpRSFC-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	5,104

3	pPpRSFC-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	5,092

4	pPpRSFC-pGAP	–	–	–	NA	Intracellular	NA	Zeocin	3,771

5	pPpRSFC-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	Zeocin	4,035

6	pPpRSFC-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	Zeocin	4,023

7	pPpRSFC-N-eGFP	eGFP	N	240	No	Intracellular	NA	Zeocin	5,584

8	pPpRSFC-C-eGFP	eGFP	C	239	No	Intracellular	NA	Zeocin	5,584

9	pPpRSFC-MFalpha-N-eGFP	eGFP	N	239	No	Secretory	Yes	Zeocin	5,848

10	pPpRSFC-MFalpha-C-eGFP	eGFP	C	239	No	Secretory	Yes	Zeocin	5,848

11	pPpRSFC-N-Myc	MYC	N	11	No	Intracellular	NA	Zeocin	4,870

12	pPpRSFC-C-Myc	MYC	C	10	No	Intracellular	NA	Zeocin	4,870

13	pPpRSFC-MFalpha-N-Myc	MYC	N	10	No	Secretory	Yes	Zeocin	5,134

14	pPpRSFC-MFalpha-C-Myc	MYC	C	10	No	Secretory	Yes	Zeocin	5,134

15	pPpRSFC-N-FLAG	FLAG	N	9	No	Intracellular	NA	Zeocin	4,864

16	pPpRSFC-C-FLAG	FLAG	C	8	No	Intracellular	NA	Zeocin	4,864

17	pPpRSFC-MFalpha-N-FLAG	FLAG	N	8	No	Secretory	Yes	Zeocin	5,128

18	pPpRSFC-MFalpha-C-FLAG	FLAG	C	8	No	Secretory	Yes	Zeocin	5,128

19	pPpRSFC-N-His-ncs	His	N	7	No	Intracellular	NA	Zeocin	4,858

20	pPpRSFC-C-His-ncs	His	C	6	No	Intracellular	NA	Zeocin	4,858

21	pPpRSFC-MFalpha-N-His-ncs	His	N	6	No	Secretory	Yes	Zeocin	5,122

22	pPpRSFC-MFalpha-C-His-ncs	His	C	6	No	Secretory	Yes	Zeocin	5,122

23	pPpRSFC-N-His	His	N	7	Yes	Intracellular	NA	Zeocin	4,879

24	pPpRSFC-C-His	His	C	6	Yes	Intracellular	NA	Zeocin	4,879

25	pPpRSFC-MFalpha-N-His	His	N	6	Yes	Secretory	Yes	Zeocin	5,143

26	pPpRSFC-MFalpha-C-His	His	C	6	Yes	Secretory	Yes	Zeocin	5,143

27	pPpRSFC-N-MBP	MBP	N	367	Yes	Intracellular	NA	Zeocin	5,959

28	pPpRSFC-C-MBP	MBP	C	366	Yes	Intracellular	NA	Zeocin	5,959

29	pPpRSFC-MFalpha-N-MBP	MBP	N	366	Yes	Secretory	Yes	Zeocin	6,223

30	pPpRSFC-MFalpha-C-MBP	MBP	C	366	Yes	Secretory	Yes	Zeocin	6,223

31	pPpRSFC-N-Strep	Strep	N	9	Yes	Intracellular	NA	Zeocin	4,885

32	pPpRSFC-C-Strep	Strep	C	8	Yes	Intracellular	NA	Zeocin	4,885

33	pPpRSFC-MFalpha-N-Strep	Strep	N	8	Yes	Secretory	Yes	Zeocin	5,149

34	pPpRSFC-MFalpha-C-Strep	Strep	C	8	Yes	Secretory	Yes	Zeocin	5,149

35	pPpRSFC-HIS	–	–	–	NA	Intracellular	NA	HIS4	7,683

36	pPpRSFC-HIS-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	7,947

37	pPpRSFC-HIS-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	7,935

38	pPpRSFC-HIS-pGAP	–	–	–	NA	Intracellular	NA	HIS4	6,614

39	pPpRSFC-HIS-pGAP-MFalpha	–	–	–	NA	Secretory	Yes	HIS4	6,878

40	pPpRSFC-HIS-pGAP-MFalpha-noEAEA	–	–	–	NA	Secretory	No	HIS4	6,866


Characteristic	Value

Total number	35

Median age (IQR) in months	20 (16–22)

Females (%)	19 (54%)

Median children in household (range)	3 (1–6)

Smokers in household (%)	11 (31%)

Received 3 doses of pentavalent vaccine	91.4%

Received at least 1 dose of pentavalent vaccine	100.0%


#	Assumption

1	There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012)

2	Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys

3	The urinary excretion (Qurine) is similar for all compounds

4	Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data

5	The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules

6	The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012)

7	All rate equations are to be described as mass action law


	MOCOS

c.1881delG /c.1782delG

	G/G	G/del	del/del

Affected animals			4

Obligate carriers		3

Tyrolean Grey population controls	1151	50

Controls of other breedsa	1225

Total	2376	53	4


Health Claims (Dedicated Children’s Channels)	2010 (%)	% Change v 2008 (+/−)	2010 All Channels (%)

Contains essential nutrients e.g., calcium, vitamins, antioxidants	39.7	+29	33.4

Part of your five a day	28.9	+4.9	10.3

Organic	10.4	+8.8	5.0

Wholegrain	8.3	−11.8	7.8

Low fat	4.7	+2.8	9.8

No added sugar	3.7	−0.5	2.1

Contains only natural ingredients	3.1	−12.2	15.9

Contains fibre	0.6	+0.6	1.3

Is low calorie/light	0.6	−5.1	5.1


Configuration	Packets Received per Second

CSR1	CSR2	CSR3	Average

CSR devices transmit each packet one	0.62	1.41	1.08	1.04

CSR devices transmit each packet three times	1.16	1.76	1.91	1.61


Surface	Contact angle (deg.)	Contact angle hysteresis (deg.)	Sliding angle (deg.)

TO-SHS	169±4	45±15	>45

TO-SLIPS	124±1	1.4±0.5	3.0±0.3


Pool	DMRs (Number)	DMRs (%)

Bulgarian females (patients/controls)	293	1.1

Bulgarian males (patients/controls)	948	3.4

Serbian females (patients/controls)	947	3.4

Serbian males (patients/controls)	944	3.4


Author	Patient (n) (age/sex)	Procedure	Cardiac rhythm	Cause	Management	Outcome

Chowdhury and West [3]	50 y ♀	Awake craniotomy (frontal tumor)	Bradycardia, asystole (25 s)	TCR (scalp traction)	Release scalp traction; cessation propofol and remifentanil infusions	No neurological deficit

Prabhu et al. [4]	65 y ♂	Awake craniotomy (temporal tumor) 	Bradycardia and asystole (8–10 s × 2 times)	TCR (dura cautery)	Cessation of cautery, atropine	No neurological deficit

Sinha et al. [5]	18 y ♂	Epilepsy surgery 	Bradycardia (2 episodes), asystole (9 s)	↑Parasympathetic response 2° to amygdala resection; warm and cold saline irrigation	Atropine; cessation of stimulus	No neurological deficit

Sato et al. [6]	6/42 [18–34 y; ♀ = 3, ♂ = 2]	Epilepsy surgery	Sinus bradycardia (<1 min)	↑Parasympathetic tone 2° to limbic stimulation	Procedure interruption; atropine	No neurological deficit

Tyler et al. [7]	22 y ♀	Craniotomy (parietal tumor)	Asystole	Intracranial hematoma (dural closure)	Hematoma evacuation	No neurological deficit

Wasnick et al. [8]	70 ♂	Epidural suction drain	Severe bradycardia	Intracranial hypotension	Release of suction	No neurological deficit

Alfery et al. [9]	18 ♀	VP shunt	VT, VF	Intracranial hypotension	Lidocaine, CPR	No neurological deficit

Karamchandani et al. [10]	65 ♀	Subgaleal suction drain	Multiple severe bradycardia	Intracranial hypotension	Release of suction, atropine	No neurological deficit

Bhagat et al. [11]	2 patients[both 60 ♂]	Subgaleal suction drain	Severe bradycardia, Asystole	Intracranial hypotension	Release of suction, atropine	No neurological deficit


Complications	Group 1	Group 2

To adult	To pediatrics	En-bloc	Single

Renal vein thrombosis	—	1 (early nephrectomy)	—	2 (graft loss)

Renal arterial thrombosis	1 (graft loss)	—	—	—

Significant lymphocele	1 (percutaneous drainage)	—	1 (percutaneous drainage)	1

Ureteral fistula	1 (surgical repair)	—	—	1 (surgical repair)

Ureteral stenosis	1 (surgical repair)	—	—	1 (surgical repair)


Gene	F/R	Primer sequence	Position	Tm

PEPT1	Forward	CCCTGAAGTGAAGGTGTTTGAAGATA	1772–1797	60.6

NM_005073	Reverse	GAATTGGCCCCTGACATGAA	2168–2188	59.3

PEPT2	Forward	CTACCACAATATGCCCTGGTTACA	1894–1917	58.8

NM_001145998	Reverse	GCCACTGAACTGTGCCACAA	2045–2064	59.3

ALAS1	Forward	GGATTCGAAACAGCCGAGTG	1371–1390	59.3

NM 000688	Reverse	GAAGGTGATTGCTCCAAACTCAT	1542–1564	58.3

ALAD	Forward	CCTCGGTTCCAACCAACTGAT	157–177	59.8

NM_000031	Reverse	GATAGGCTGTATGTCATCAGGAACA	319–343	58.2

HMBS	Forward	CAAGGACCAGGACATCTTGGAT	835–856	58.9

NM_000190	Reverse	CCAGACTCCTCCAGTCAGGTACA	984–1006	59.2

UROS	Forward	TCAGCACTGCCTCTTCTATTTCC	668–691	58.7

NM_000375	Reverse	CTGGGTGTGCAACTGTCTGATAC	761–789	58.3

UROD	Forward	CGGGAGTGTGTGGGGAA	982–998	57.2

NM_000374	Reverse	AAGCAGACGTGAGTGTTTATGCA	1178–1200	58.6

ABCB6	Forward	CAGAAGGGCCGTATTGAGTTTG	2033–2054	59.6

NM_005689	Reverse	ATTGTCGGCGATGGTGTCA	2308–2326	59.5

CPOX	Forward	GGCGGAGATGTTGCCTAAGAC	401–421	59.7

NM_000097	Reverse	AATGCTCACCCCAGCCTTTT	709–728	59.5

PPOX	Forward	CAGGAGTCCTGGGAATCGTGTA	1251–1272	59.9

NM_000309	Reverse	TGCCTAGCTGACTCTAGTTTTTGC	1509–1533	58.1

FECH	Forward	GGAAATCCATTGTTCTCTAAGGC	1252–1274	57.0

NM_001012515	Reverse	CTAAATAACACCCTCTCCACATCG	1462–1485	57.8

ABCG2	Forward	CTAAGCAGGGACGAACAATCATC	1188–1210	58.8

NM_004827	Reverse	TCCTGCTTGGAAGGCTCTATG	1447–1467	58.2

HIF-1alpha	Forward	GGCGCGAACGACAAGAA	420–436	58.0

NM 001530	Reverse	CAAAACCATCCAAGGCTTTCA	682–702	58.7

HO-1	Forward	GCTCAAAAAGATTGCCCAGAA	518–538	58.1

NM_002133	Reverse	TCACATGGCATAAAGCCCTACA	926–947	59.1


	Pain score ribs	Pain score iliac crest

Hospital admission, oral analgesics	5	Not applicable

Pre-operative, with epidural catheter	3-6	Not applicable

Post-operative day 3, with epidural catheter	1-2	4-5

Discharge home, oral analgesics	1-2	3-5


 	Vascularization ≤ 1 point

No	Yes

Target IOP not reached	No	39	3

Yes	10	5

Agreement	Kappa	 	.31


Assembler	Sequencing	Strains	Insert size	Read length (bp)	Number of reads	Raw read coverage	Assembled bases (Mb)	Contig coverage	Contig N50

FuzzyPath	Illumina	CAST/Ei	200 bp	36	173 million	65×	76.03	80.0%	2,315

Velvet*	Illumina	CAST/Ei	200 bp	36	173 million	65×	58.09	61.15%	391

ABySS	Illumina	CAST/Ei	200 bp	36	173 million	65×	72.80	76.63%	1,022

FuzzyPath	Illumina	A/J	200 bp	36	112 million	42×	55.87	58.8%	959

Phusion	Capillary	A/J	3-5 kb	400-900	357,100	2.5×	81.2	85.5%	3,377

FuzzyPath	Hybrid	A/J†	Hybrid†	Hybrid†	Hybrid†	Hybrid†	85.54	90.0%	5,793


	Infant HIV exposure category	p-Valueb

HEU (N = 60)	HUU (N = 72a)

Maternal characteristics

Mean (SD) maternal age at enrollment	28.0 (5.1)	25.9 (6.2)	0.05

Substance use during pregnancy, N (%)

Alcohol	13 (21.7)	8 (11.1)	0.15

Tobacco	16 (26.7)	10 (13.9)	0.08

Marijuana	4 (6.7)	0 (0.0)	0.04

Crack or cocaine	2 (3.3)	0 (0.0)	0.20

Maternal employment, N (%)	22 (36.7)	41 (56.9)	0.02

Mean (SD) years of completed education	7.6 (3.2)	9.3 (2.4)	0.001

Mean (SD) number of prior pregnancies	2.3 (1.9)	1.2 (1.3)	<0.0001

Mean (SD) parity	1.8 (1.6)	1.0 (1.1)	0.001

Mean (SD) number of people living in the household	4.4 (2.0)	4.7 (1.7)	0.32

Mean (SD) CD4 count (cells/mm3) at hospital discharge	563.9 (266.7)	–	–

Mean (SD) CD4% at hospital discharge	32.0 (9.4)	–	–

Mean (SD) viral load (log10 copies/mL) at hospital discharge	2.23 (0.81)	–	–

Viral load <400 copies/mL at hospital discharge, N (%)	51 (85.0)	–	–

ARV use during pregnancy, N (%)		–	–

Zidovudine monotherapy	25 (41.7)	–	–

Combination antiretrovirals	35 (58.3)

Infant characteristics

Mean (SD) gestational age at birth (weeks)	38.7 (1.2)	39.2 (1.4)	0.01

Female gender, N (%)	25 (41.8)	36 (50.0)	0.38

Mean (SD) birth weight (g)	3176.4 (381.5)	3346.5 (422.7)	0.02

Small for gestational age (<10th percentile), N (%)	2 (3.3)	0 (0.0)	0.20

Large for gestational age (>90th percentile), N (%)	7 (11.7)	16 (22.2)	0.17

Not breastfeeding, N (%)	60 (100)	1 (1.4)	<0.0001


SOCIODEMOGRAPHIC AND CLINICAL CHARACTERISTICS	TREATMENT GROUP(N = 22)MEAN ± SD	WAITING LIST CONTROL GROUP (N = 24)MEAN ± SD	P

Age (years)	48.6 ± 11.2	53.0 ± 11.4	0.20

Sex (F/M)	15/7	20/4	0.27

BMI (kg/m2)	24.9 ± 4.0	24.1 ± 3.1	0.47

Pain at rest (PR)	45.5 ± 20.9	42.3 ± 18.0	0.58

Duration of neck pain (years)	6.3 ± 6.1	8.0 ± 7.6	0.41

Expected effectiveness of cupping therapy(VAS from 0 = not effective at all to 100 = highly effective)	82.8 ± 13.6	72.4 ± 21.3	0.06


Patient no. (with cartilage damage)	Teres ligament	Joint capsule

 	S100	Substance P	S100	Substance P

1.	+	+	-	-

4.	-	+	+	-

5.	+	+	+	+

9.	+	+	-	-

11.	+	+	+	+

12.	+	+	-	-

15.	+	+	-	-

16.	+	+	+	-

17.	-	-	-	+


Extracted peatland drains

Linear validation dataset	Drain	No drain		Total	Producer accuracy

Drain	193	131		324	0.60

No drain	39	2637		2676	0.99

			2830

Total	232	2768		3000

User accuracy	0.83	0.95

Kappa statistic	0.66			OA	0.94


Genes	Identity	Major function

Genes that promote neuronal integrity during aging

daf-16	FoxO transcription factor	Upregulation of stress resistance genes

hsf-1	Heat shock transcription factor	Upregulation of small heat shock protein expression

mec-1	EGF and Kunitz domain-containing ECM protein	Mechanosensory transduction, nerve attachment

mec-2	Stomatin-like	Mechanosensory transduction

mec-4	DEG/ENaC family sodium channel	Mechanosensory transduction

mec-5	Atypical collagen	Mechanosensory transduction, nerve attachment

mec-6	Paraoxonase	Mechanosensory transduction

mec-9	EGF and Kunitz domain-containing ECM protein	Mechanosensory transduction, nerve attachment

mec-10	DEG/ENaC family sodium channel	Mechanosensory transduction

mec-12	α-tubulin	Mechanosensory transduction, axon transport

jkk-1	JNK kinase	Activation of JNK; synaptic vesicle localization

jnk-1	c-Jun N-terminus kinase (JNK)	Heat and stress response; locomotion

mek-1	Mitogen activated protein kinase (MAPK) kinase/MKK7	Stress and starvation response

lmn-1	Laminin	Regulation of nuclear organization and function

ptl-1	Tau/microtubules-associated protein	Microtubule stabilization?

unc-13	Munc-13	Synaptic vesicle fusion

unc-18	Munc-18	Synaptic vesicle docking

Genes that accelerate neuronal aging

daf-2	Insulin-like growth factor receptor	Larval development, dauer formation, etc

dgk-1	Diacylglycerol kinase	Inhibition of synapse transmission

slo-1	BK-type potassium channel	Muscle inactivation, neuronal excitability, etc


Ribosomal protein gene	Chromosomal assignment in C. elegans	Number of 5' codons omitted from analysis	Coding nucleotides used for analysis

rpl-1	III	3	642

rpl-2	V	0	783

rpl-10	II	5	630

rpl-14	I	5	402

rpl-16	III	5	597

rpl-23	III	5	408

rpl-26	II	3	423

rpl-27	I	6	393

rpl-27a	I	8	420

rpl-28	V	7	387

rpl-29	IV	0	189

rpl-30	I	4	339

rpl-31	I	8	345

rpl-32	II	8	381

rpl-34	IV	4	330

rpl-35	III	8	348

rpl-38	V	6	195

rpl-39	V	8	132

rps-1	III	6	762

rps-8	IV	3	618

rps-14	III	8	435

rps-20	I	0	357

rps-21	III	0	267

rps-24	IV	0	396

rps-25	IV	7	336

rps-27	V	0	255

rps-28	IV	0	201

Total number of nucleotides:			10,971


Primary antibody	Manufacturer	Cat. number	Dilution	Source

OCT4	Abcam	ab18976	1/250	Rabbit

NANOG	Abcam	ab21624	1/100	Rabbit

SSEA4	Abcam	ab16287	1/100	Mouse

TRA-1-81	Abcam	ab16289	1/100	Mouse

TRA-1-60	Abcam	ab16288	1/100	Mouse

SOX1	Abcam	ab87775	1/200	Rabbit

PAX6	DSHB	3B5	1/50	Mouse

OTX2	Abcam	ab21990	1/500	Rabbit

LHX2	Santa Cruz Biotechnology	sc-81311	1/200	Mouse

SIX3	Rockland	600-401-A26	1/500	Rabbit

MCM2	Abcam	ab4461	1/400	Rabbit

CHX10	Millipore	ab9016	1/200	Sheep

FIBRONECTIN	Abcam	ab2413	1/200	Rabbit

ZO-1	Thermo Fisher	33-9100	1/400	Mouse

BRN3	Santa Cruz Biotechnology	sc-6026	1/200	Goat

AP2	DSHB	3B5a	1/35	Mouse

PROX1	Abcam	ab101851	1/2000	Rabbit

PKC-α	Abcam	ab32376	1/2000	Rabbit

CRALBP	Abcam	ab15051	1/500	Mouse

Rhodopsin	Abcam	ab3267	1/200	Mouse

S opsin	Gift from Dr. Jeremy Nathans	/	1/5000	Rabbit

L/M opsin	Gift from Dr. Jeremy Nathans	/	1/5000	Rabbit

Recoverin	Millipore	ab5585	1/500	Rabbit

PDE6α	Abcam	ab5665	1/100	Rabbit

Gtα-1	Santa Cruz Biotechnology	sc-136143	1/2000	Mouse


Task	Satisfactory	Unsatisfactory

(1) Performs a “time-out” and places monitors on patient (pulse oximetry and NIBP).	—	—

(2) Verifies that spinal kit tray, nonsterile and sterile gloves (correct size), and cleansing solution are present. 	—	—

(3) Palpates the superior aspects of the iliac crests and identifies the intersection at the L4 spinous process with nonsterile gloves on. Marks position at the L3/L4 or L4/L5 interspace.	—	—

(4) Cleans the overlying skin with chlorhexidine.	—	—

(5) Opens the spinal tray before placing sterile gloves on.	—	—

(6) Puts on sterile gloves with proper technique.	—	—

(7) Applies sterile drapes.	—	—

(8) Draws up lidocaine in the 3cc syringe and bupivacaine in the 5cc syringe. Administers local anesthesia in a wheal at the previously marked site.	—	—

(9) Injects more anesthetic in the correct location and angle.	—	—

(10) Inserts the introducer needle in the middle of the interspace with a slight cephalad angulation of 10 to 15 degrees. The bevel of the spinal needle should be in the sagittal plane.	—	—

(11) Advances spinal needle through anatomic structures until the subarachnoid space is reached. May experience a popping sensation as the ligamentum flavum is crossed.	—	—

(12) Withdraws the stylet each time a pop is felt to assess for CSF flow.	—	—

(13) Confirms CSF flow by aspiration before and after injecting anesthetic.	—	—

(14) Removes the spinal and introducer needle together once completed. 	—	—

(15) Applies pressure with the provided 2 × 2 gauze and assesses good hemostasis.	—	—

(16) Removes the drape, lays the patient, and observes vitals. Disposes of all sharps and biohazard material appropriately. 	—	—


		KEGG pathway	Count	P value

HFF1_24 h vs HFF1	Up-regulated gene	hsa04622: RIG-I-like receptor signaling pathway	6	9.35E-05

hsa04620: Toll-like receptor signaling pathway	5	0.0043

hsa04623: Cytosolic DNA-sensing pathway	4	0.0057

HFF1_48 h vs HFF1	Up-regulated gene	hsa04620: Toll-like receptor signaling pathway	6	0.0209

hsa04622: RIG-I-like receptor signaling pathway	5	0.0249

Down-regulated gene	hsa05410: Hypertrophic cardiomyopathy (HCM)	4	0.0479

HFF1_72 h vs HFF1	Up-regulated gene	hsa00330: Arginine and proline metabolism	6	0.0076

hsa00480: Glutathione metabolism	5	0.0287

hsa00250: Alanine, aspartate and glutamate metabolism	4	0.0349

Down-regulated gene	hsa04510: Focal adhesion	13	4.57E-05

hsa04810: Regulation of actin cytoskeleton	10	0.0056

hsa05200: Pathways in cancer	11	0.0272

ES vs HFF1	Up-regulated gene	hsa05217: Basal cell carcinoma	14	9.58E-06

hsa04310: Wnt signaling pathway	22	1.28E-04

hsa05200: Pathways in cancer	36	2.29E-04

hsa00330: Arginine and proline metabolism	10	0.0029

Down-regulated gene	hsa04510: Focal adhesion	40	8.73E-08

hsa00520: Amino sugar and nucleotide sugar metabolism	13	1.09E-04

hsa04512: ECM-receptor interaction	18	2.52E-04

hsa04142: Lysosome	20	0.0019

iPS vs HFF1	Up-regulated gene	hsa04310: Wnt signaling pathway	16	2.39E-04

hsa05217: Basal cell carcinoma	8	0.0029

hsa00250: Alanine, aspartate and glutamate metabolism	6	0.0041

hsa00260: Glycine, serine and threonine metabolism	6	0.0041

Down-regulated gene	hsa04510: Focal adhesion	56	1.46E-11

hsa04512: ECM-receptor interaction	27	3.06E-07

hsa00520: Amino sugar and nucleotide sugar metabolism	16	2.84E-05

hsa04810: Regulation of actin cytoskeleton	42	1.43E-04


Author (reference number)	Gender	GA (wks)	Clinical features of LCH involvement	Outcome (survival)

Vade et al. [10]	F	35	Skin, hepatosplenomegaly, pulmonary failure	Died (9 days)

Gee et al. [11]	M	33	Skin, pulmonary failure	Died (36 hrs)

Aviner et al. [12]	F	32	Skin, followed by multiorgan failure	Died (26 days)

Lee et al. [8]	M	36	Hydrops fetalis, skin, multiorgan failure	Died (12 days)

Cheng et al. [9]	M	33	Hydrops fetalis, skin, pleural effusion	Died (36 hrs)

Herbrüggen et al. [13]	M	35	Skin, at 3 months, pulmonary and thymic mass	Alive

Present case	F	33	Skin, hypovolemic shock, pulmonary failure	Died (57 hrs)


	Ontology 8a – Regex	Ontology 7b – Voting

Total number of top-level terms	662		1886

Number of sampled top-level terms	200	30.2% of total	200	10.6% of total

Number of sampled top-level terms relevant to animal behaviour	84	42% of sample	82	41% of sample

Proportionate number of top- level animal behaviour terms in the whole ontology	278		773

Number of sampled top-level an imal behaviour terms not found in the other ontology	44	22% of sample	77	38.5% of sample

Proportionate number of top- level animal behaviour terms in the whole ontology not found in the other ontology	145		727


Composites	Relatives items

Parental sensitivity	Acknowledging; imitating; elaborating; parent gaze; positive affect; vocal appropriateness, clarity; appropriate range of affect; resourcefulness; praising; affectionate touch; supportive presence; infant led interaction

Parent intrusiveness	Forcing-physical manipulation; overriding, intrusiveness; parent negative affect, anger; parent anxiety; criticizing; parent-led interaction

Parent limit setting	Consistency of style; resourcefulness; appropriate structure, limit setting

Child compliance	Compliance to parent; reliance on parent for help; on-task persistence

Child withdrawal	Child negative emotionality, fussy; withdrawal; labile affect; avoidance of parent

Child engagement	Joint attention; child positive affect; affection to parent; alertness; fatigue; vocalizations, verbal output; initiation; competent use of the environment; creative-symbolic play; infant-led interaction

Dyadic joint negative state	Parent negative affect, anger; hostility; child negative emotionality, fussy; withdrawal, labile affect; fatigue; constriction; tension

Dyadic reciprocity	Parent gaze; positive affect; praising; affectionate touch; joint attention; child positive affect; vocalization, verbal output; initiation; dyadic reciprocity; adaptation-regulation; fluency